

# PASPCR

## Newsletter

---

---

Volume 8 Number 2

June, 2000

---

---

---

### Introduction . . .

The **PASPCR Newsletter** is published quarterly and is intended to serve as a means of communication for the members of our Society. As such, we invite our membership to actively contribute to it. If you attend a scientific meeting and heard results which you think will be of interest to the membership of the **PASPCR**, please write a few paragraphs summarizing what was presented and share it with us. Any information on up-coming meetings of interest will also be included. We also want to note any change of affiliation or address that you may have had to help us keep our membership list up-to-date. This is **your Newsletter**, and we depend upon you to help us make sure it best serves the Society's needs. Contributions and comments can be sent to Bill Oetting, preferably by Email, to [bill@lenti.med.umn.edu](mailto:bill@lenti.med.umn.edu).

The **PASPCR Web** page is the major, up-to-date source of current information for the PASPCR membership. The URL address to our home page is <http://www.cbc.umn.edu/paspcr>. The PASPCR Web page contains information about the PASPCR including the goals, ByLaws and Rules of the Society, future meetings, past issues of the **PASPCR Newsletter** as well as links to other related sites including the InterPig DataBase, the International Federation of Pigment Cell Societies (IFPCS) and the regional Pigment Cell Societies from Europe and Japan. In addition, an updated PASPCR membership directory is available on the PASPCR Web page; please notify us if you wish any or all of your information to be modified or deleted on that site. The PASPCR home page also includes positions available and positions wanted. Postings for **Positions Available** is open to all individuals so long as the position is related to pigment cell research. Postings for **Positions Wanted** will be open only to members of the PASPCR or its sister societies (JSPCR and ESPCR). Please provide an expiration data for any submitted postings. If there is additional information that you wish to have added to this web page, please let us know. Send any comments and/or suggestions to the PASPCR WebMaster, Bill Oetting at [bill@lenti.med.umn.edu](mailto:bill@lenti.med.umn.edu).

**Note:** The IFPCS webpage has a new URL address at <http://www.cbc.umn.edu/ifpcs>.

### IN THIS ISSUE . . . . .

Introduction.....	p 1
PASPCR Contact Information.....	p 2
Calendar of Events .....	p 2
Welcome New Members.....	p 3
Corporate Sponsors .....	p 3
Invitation to Host the 19 <sup>th</sup> IPCC.....	p 3
From the Editor - Pigment Cell Research.....	p 3
Positions Wanted / Available.....	p 4
Letter from Lynn and Estela.....	p 5
Program for the IX <sup>th</sup> Annual PASPCR Meeting.....	p 6
Bibliography.....	p 13

**PanAmerican Society for  
Pigment Cell Research**

c/o **Dr. James J. Nordlund**  
Department of Dermatology  
University of Cincinnati  
231 Bethesda Avenue  
Cincinnati, OH 45267-0592  
FAX: (513) 558-0198

**Officers**

Richard A. King  
*President*  
Zalfa Abdel-Malek  
*President-Elect*  
James J. Nordlund  
*Secretary/Treasurer*

**Council Members**

Jean L. Bologna  
Mary K. Cullen  
Meenhard Herlyn  
Helene Z. Hill  
Estela E. Medrano  
Randy Morrison  
William J. Pavan  
Vijay Setaluri  
Giselle Thibaudeau

**IFPCS Representative**

Sally Frost-Mason  
*past-President PASPCR*

The **PASPCR Newsletter** is published quarterly; for further information or to submit articles, contact:

**Publications Committee:**

**Mary K. Cullen, MD**

Washington University School of Medicine  
Departments of Cell Biology & Dermatology  
660 South Euclid, Box 8228  
St. Louis, MO 63130  
Phone: (314) 362-1082  
Email: mkcullen@cellbio.wustl.edu

**Randall L. Morrison, PhD**

Hood College  
Department of Biology  
401 Rosemont Avenue  
Frederick, MD 21701  
Phone: (301) 696-3659  
Email: rmorrison@nimue.hood.edu

**Vijayasaradhi Setaluri, PhD**

Wake Forest University School of Medicine  
Department of Medicine  
Winston-Salem, NC 27157  
Phone: (336) 716-3273  
Email: setaluri@bgsm.edu

**Calendar of Events :**

**Jun 25 - 28, 2000** IX<sup>th</sup> Annual Meeting of the PanAmerican Society for Pigment Cell Research, to be held in College Station, TX  
**Contact:** Dr. Lynn Lamoreux, Department of Veterinary Pathobiology, The Texas Veterinary Medical Center, Texas A & M University, College Station, TX 77843-4467;  
Phone: (409) 845-6084  
Fax: (409) 845-9972  
Email: llamoreux@vetmed.tamu.edu.

**Sept 28 - Oct 1, 2000** 9<sup>th</sup> Annual Meeting of the European Society for Pigment Cell Research, to be held in Ulm, Germany  
**Contact:** Prof. R.U. Peter, University of Ulm (BWK) Dept of Dermatology Oberer Eselsberg 40 D - 89081 ULM  
Tel: 49-731 502-3770  
Fax: 49-731 502-3772  
E-mail: ralf.peter@medizin.uni-ulm.de

**Dec 5-6, 2000** 13<sup>th</sup> Meeting of the Japanese Society for Pigment Cell Research, to be held in Sapporo, Japan,  
**Contact:** K Jimbow

**Feb 28, March 3, 2001** 5<sup>th</sup> World Conference on Melanoma : Venice, Italy, February 28 - March 3  
**Contact:** Dr Mario Santinami Secretary General 5<sup>th</sup> World Conference on Melanoma Casa di Cura S. Pio X Via F. Nava 31 I - 20159 Milano  
Phone/Fax: 39-02-69516449  
E-Mail : info@melanoma2001.org

**Jun 25 - 28, 2001** X<sup>th</sup> Annual Meeting of the PanAmerican Society for Pigment Cell Research, to be held in Minneapolis, MN  
**Contact:** Dr. Richard A. King, Department of Medicine, Box 485 Mayo, 420 Delaware St. S.E., Minneapolis, MN 55455;  
Phone: (612) 624-0144  
Fax: (612) 624-6645  
Email: king@mail.ahc.umn.edu.

**2002** The XVIII<sup>th</sup> International Pigment Cell Conference, to be held in The Hague, Holland.  
**Contact:** Dr. Stan Pavel, President ESPCR, University Hospital Leiden, Dept of Dermatology, PO Box 9600, NL - 2300 RC LEIDEN  
Phone: 31-(71) 526 1952  
Fax: 31-(71) 524 8106;  
E-mail: SPavel@algemeen.azl.nl

**Sept 3-7, 2003** XI<sup>th</sup> Annual Meeting of the PanAmerican Society for Pigment Cell Research, to be held in Wood's Hole, MA.

---

## Welcome to New Members

by James J Nordlund

We welcome the following new member to the PASPCR . . .

**Esthy R. Almodovar-Ramirez, B.S., Achim H. Krauss, Ph.D., John Nip, Ph.D., Michael J. Pratt, Licheng Shi, M.S., and John C. Zhuang, Ph.D.**

If anyone is interested in joining our Society or wishes to sponsor a member, application forms can be obtained from Dr. James J. Nordlund at the PASPCR Secretary/Treasurer's office.

---

## Corporate Sponsors

by James J Nordlund

The PASPCR would like to acknowledge and thank our Corporate Sponsors; the list below reflects contributions over the past 2 years. Financial gifts from these sponsors have allowed our Society to increase benefits to the membership far out of proportion to the actual dues collected from members. Monies contributed by these sponsors have been used over the years to support various PASPCR functions including our Young Investigator Award program, meeting travel stipends, annual meeting expenses and this Newsletter.

### *GOLD Corporate Patrons*

Procter and Gamble Co  
Shiseido Co, Ltd

### *SILVER Corporate Patrons*

Avon Products, Inc  
Galderma Laboratories, Inc  
Stiefel Laboratories  
Combe, Inc.

---

## 19<sup>th</sup> International Pigment Cell Conference

The PASPCR and IFPCS invite members of the PASPCR to submit proposals for hosting the 19<sup>th</sup> IPCC. In 2005 the IPCC will be held in the Americas (North, Central or South). Those interested in hosting and chairing this meeting should prepare their invitation to present to the Council of the PASPCR meeting at College Station, Texas during the June 25-28, 2000.

The interested parties should present the advantages of hosting the meeting in their city and university; general plans and topics or themes; proposed levels of funding and sources of funding; plans for organizing the scientific meeting; conference facilities; hotels and recreation or other topics that will help the Council of the PASPCR select the best site for this meeting.

Vince Hearing at NIH and Jim Nordlund at Cincinnati both have indicated their interests in hosting the meeting. Others interested should contact Dick King at the University of Minnesota to indicate their interest.

---

## From the Editor - *Pigment Cell Research*

**WHAT DO YOU MEAN** that you haven't subscribed personally yet to ***Pigment Cell Research*** or gotten your University's Library to do so? Are you an observer in this game or are you in it to compete? The members' subscription cost of \$95 is less than 2 boxes of sterile gloves or five 20-mer PCR primers.

So far you've already missed State-of-the-Art Reviews on Melanocyte Proliferation and Differentiation by Halaban and Ballotti, respectively, and on Melanosomal Targeting by Setaluri. You are in line to miss Reviews coming up this year by Jimbow, Fujii, Lamoreux and Hoening on Trafficking of TRPs, Regulation of Chromatophore Motility, Congenic Animal Models and the Roles of Adapter Proteins in Melanocytes. Each issue has a Review on a Pigment Gene and its effect on human pigmentation; this year's Gene Reviews include *pale ear* and Hermansky Pudlak (Spritz), *Mitf* and Waardenburg Syndrome Type 2 (Tachibana), *MC1R* and constitutive pigmentation (Rees), *tyrosinase* and Oculocutaneous Albinism Type 1 (Oetting), and *EDNRB/ET3* and Hirschsprung Disease Type 2 (Chakravarti).

Are you working in your lab using techniques from the Middle Ages or are you up to date in your methods and approaches? Our Innovative Technology Reviews this year are covering Genome Display Arrays, DNA Repair by RDO nucleotides, Microarray Technology, High Resolution Time Lapse Micrography, Tet-Inducible Gene Promoters, and Antibodies to Study Melanoblast Development (by Oetting, Yoon, Pavan, Hammer, Shin and Nishikawa).

And that doesn't even touch the Original Research Articles that are being published in each issue. Nor does it cover the 28 Articles in the Proceedings from the Nagoya International Pigment Cell Conference (most of the Invited Lectures are represented in that 200 page Supplement coming soon to subscribers). If you couldn't afford the time or funds to attend that meeting in person, you really missed something but you can get some of the critical information presented there from the Supplement (nonsubscribers can purchase copies if they wish - contact Dr. Wakamatsu).

Sure, you can see the titles of all these Reviews and Original Research Articles as they come out and you can even access their Abstracts (and for that matter Abstracts from all past issues) from the **Pigment Cell Research** Web site ([www.pigment.org](http://www.pigment.org)). You can even sign up to be automatically notified by Email about articles as they are published. You can now even purchase individual articles from **Pigment Cell Research OnLine** ([www.ingenta.com](http://www.ingenta.com)) if you don't subscribe. But why would you want to rely on other sources, or even on your colleagues, when you can have your very own soft, warm and attractive copy to keep forever?

My Editorial Office is now lining up Reviews and Special Articles for next year. I'd welcome input on what you'd like to see in your journal in the future. Let me know at [editor@pigment.org](mailto:editor@pigment.org).

**Vince Hearing**, Editor

---


## Positions - Wanted and Available :

**Postdoctoral Fellows - Cancer and Developmental Biology** - Two NIH-funded positions are available for fellows interested in studying the Hedgehog signaling pathway in development and disease using skin as a model system. One project centers on defining the function of the Hedgehog pathway during skin appendage morphogenesis (*Dev. Biol.* 205: 1-9, 1999); a second project focuses on understanding how deregulated activation of this pathway gives rise to basal cell carcinomas (*Nature Genet.* 24: 216-7, 2000). Applicants should have a solid background in molecular and cell biology, with experience in transgenic animal models desirable but not required. Interested individuals should send a CV, letter of interest, and names of three references to: Dr. Andrzej Dlugosz, University of Michigan, Department of Dermatology and Comprehensive Cancer Center, 3310 CCGC, Box 0932, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0932 Email: [dlugosza@umich.edu](mailto:dlugosza@umich.edu). The University of Michigan is an Equal Opportunity Employer.

**Postdoctoral Research Associate** - Position available to study the biology of human inherited disorders of pigmentation using gene transfer technology. The successful applicant will have a Ph.D. and/or M.D. with experience in cell biology and molecular biology. Experience in gene transfer/genome manipulation is preferred. Please send curriculum vitae along with the names of three references to Dr. Richard King, Division of Genetics, Department of Medicine, Box 485 Mayo, 420 Delaware St. S.E., University of Minnesota, Minneapolis, MN 55455. Equal Opportunity Employer.

**Postdoctoral Position** - Ph.D. in molecular biology, biophysics, genetics or biochemistry. Position available to conduct research on molecular mechanisms of cellular response to oxidative stress in human melanocytes and melanoma cells and its regulation for preventive and therapeutic indications. Contact Dr. Frank L. Meyskens Jr.,

Director, University of California-Irvine, Chao Family Clinical Cancer Research Center, 101 The City Drive,  
Orange, CA 92668, USA. Fax (714) 456-5039 Email flmeyske@uci.edu



## HOWDY FOLKS!

We're getting ready for a truly international group of experts at the upcoming 9th annual PASPCR meeting in College Station. Our colleagues will be streaming in from every continent and from all our associations, and we are looking to the meeting with eager anticipation.

You may still register on the web at the following address:

<http://ti.tamu.edu/conferences/paspcr/>

For your hotel reservations please contact the hotel directly before June 10. A block of rooms has been reserved at the Hilton College Station for your convenience. The nightly rate is \$75 for single or double occupancy. Please call 979-693-7500 to make reservations by June 10, 2000. To get the special rate, please refer your reservation to the "Pan American Pigment Cell Society" block of rooms. Reservations must be made by June 10, 2000 to secure the discounted rate. You may also go to the web site of the Hilton College Station at:

<http://www.hiltoncs.com/index-orig.htm>

Be sure to arrange travel all the way to College Station (CLL). We are not particularly close to anywhere else. (That's our charm.)

The College Station Airport is about four miles from the Hilton. The Hilton has a shuttle that can be reached by telephone 979-693-7500. Rental cars are also available at the airport, but you probably won't need a car unless you plan some touring. We recommend reserving in advance. Advantage Rent-A-Car, 979-268-1223. Avis, 979-846-9007. Driving time from Dallas-Fort Worth Airport is about four hours. Driving time from Austin Airport is about two hours.

NOTE - our area code has changed to 979 from 409. This probably will not be a problem before the meeting.

See Y'all Soon!

*Lynn Lamoreux*  
*Estela Medrano*

---

# Program for the 9th annual PASPCR meeting in College Station

## And A Big Thank you to our Sponsors

National Institutes of Health (NIAMS)	Unilever
Bristol-Myers Squibb	Anaderm-Pfizer
Proctor & Gamble	Johnson & Johnson
Shiseido	ICN
Avon	Stiefel Laboratories

Bryan/College Station Chamber of Commerce Convention and Visitors Bureau  
Department of Veterinary Pathobiology, Texas A&M University

### **PROGRAM COMMITTEE**

Dr. M. Lynn Lamoreux, Texas A&M Univ.  
Dr. Estela E. Medrano, Baylor Coll. of Med.  
Dr. Vincent Hearing, NIH  
Dr. Bill Oetting, University of Minnesota  
Dr. John Pawlek, Yale Medical School  
Dr. John Reed, Baylor College of Medicine  
Dr. Glynnis Scott, University of Rochester  
Dr. Dick Swank, Roswell Park Cancer Inst.

### **LOCAL COMMITTEE**

Dr. M. Lynn Lamoreux  
Dr. Estela E. Medrano  
Dr. John Reed  
Dr. Xiao Michelle Androulakis  
Ms. Mary Jewell  
Ms. Jennifer Kristynik

### **INVITED SPEAKERS**

Dr Shin-Ichi Nishikawa, Kyoto University, Faculty of Medicine  
Dr Osvaldo L. Pokhajcer, Instituto de Investigaciones Bioquimicas, Buenos Aires  
Dr. Shigeki Shibahara, Tohoku University School of Medicine  
Dr. Max Amoss, Texas A&M University  
Dr. Menashe Bar-Eli, MD Anderson Cancer Center  
Dr. Gregory Barsh, Howard Huges Medical Institute, Stanford Sch.Med.  
Dr. Ray Boissy, University of Cincinnati Medical College  
Dr Lynda Chin, Dana Farber Cancer Institute  
Dr. Roger D. Cone, Oregon Health Sciences University  
Dr. Colin Goding, Marie Curie Research Institute  
Dr. Hee-Young Park, Boston University School of Medicine  
Dr. Miri Seiberg, Johnson & Johnson  
Dr. George Wolff, USDHH

### **CHAIRS OF THE SESSIONS**

#### Vertebrate Genetics and Pigmentation

Roz Miltenberger, Oak Ridge National Laboratories  
Bill Pavan, NIH

Making Sense of MITF

Heinz Arnheiter, NIH

David Fisher, Dana Farber Cancer Institute



## Melanoma

Dot Bennett, St. George's Hospital Medical School, UK  
Meenhard Herlyn, The Wistar Institute  
Stan Pavel, Leiden University Medical Centre, The Netherlands  
Dennis Roop, Baylor College of Medicine

## Melanosome Genesis, Function and Transfer to Keratinocytes

Seth Orlow, NYU  
Glynis Scott, University of Rochester School of Medicine

## Signal Transduction, UV Irradiation and Pigmentation

Zalfa Abdel-Malek, University of Cincinnati Med. School  
Ruth Halaban, Yale Medical School

**Availability of rooms is 4 pm; checkout by 12 noon.**

### **SATURDAY, JUNE 24**

**4 pm** Hotel rooms available  
**4 pm to 7 pm** Registration available

### **SUNDAY, JUNE 25**

Check in time is 4 pm. You may leave your bags in Mockingbird Room D.

**8:00 am** Registration desk is open

**8:00 am - 1 pm** Please put up your posters in the Break room. They will remain for the duration of the conference.

**8:00 am - 11:00** Meeting of the Officers, International Society for Pigment Cell Research  
Mockingbird Room C

**11:00 am - 1:00** Meeting of the Council, PanAmerican Society for Pigment Cell Research  
Mockingbird Room C

**1 pm** Welcome speeches \* Theater - Co-Chair Estela Medrano opens

**1:15 - 2:00** Keynote Address Dr. Shigeki Shibahara, Tohoku University School of Medicine, MITF isoform multiplicity: Alternative promoters and their separate regulation.  
Theater

**2:00 - 2:20** Symposium: Making Sense of MITF: Multiple Roles in Human and Mouse Disorders.  
*Co-Chairs:* Heinz Arnheiter, NIH; David Fisher, Dana Farber Cancer Institute Theater

**2:20 - 2:35** William J. Pavan. Analysis of WNT signaling in melanocyte development using neural crest directed gene transfer

**2:35 - 2:50** Thomas J. Hornyak - Microphthalmia and loss of coat pigmentation from transgenic expression of a neurogenic factor in pigment cell precursors.

**2:50 - 3:05** Ling Hou - Interactions of the murine microphthalmia gene (MITF) with the dominant spotting gene (W) in melanocyte development.

**3:05 - 3:30** BREAK in break room. **POSTER VIEWING.**

**3:30 - 4:15** Invited Speaker Colin Goding - The microphthalmia-associated transcription factor and regulation of gene expression in melanocytes.

- 4:15 - 4:30** S. Brian Potterf - Involvement of SOX10 in melanoblast and melanocyte gene expression.  
**4:30 - 4:45** Dong Fang - Evidence for a repressor which blocks MITF-mediated transcriptional activation of TRP-1.
- 6:30** Reception - Oakwood Room

**MONDAY, JUNE 26, 2000**

- 8:00 am** Continental Breakfast - Break Room  
**8:30 - 8:50** Symposium: Signal Transduction, UV Irradiation and Pigmentation.  
*Co-Chairs:* Zalfa Abdel-Malek and Ruth Halaban.  
 Theater
- 8:50 - 9:35** Invited Speaker Hee-Young Park - Regulation of human melanogenesis by protein kinase C-Beta.  
 Theater
- 9:35 - 9:50** Zalfa Abdel-Malek - Towards identification of mitogen and stress-induced signaling pathways in human epidermal melanocytes.  
**9:50 - 10:05** Sheila Mac Neil -  $\alpha$ -MSH, oxidative stress and (only when all else fails) melanogenesis.
- 10:05 - 10:30** BREAK in the Break Room **POSTER VIEWING**
- 10:30 - 10:45** Elizabeth Pereira - Differential responses of human epidermal melanocytes and keratinocytes to environmental UVB radiation and arsenic.  
**10:45 - 11:00** Sumayah Jamal - Endothelin-1: A potential link between ultraviolet irradiation and melanoma invasion.  
**11:00 - 11:15** Masaki Yoshida - Histamine involved with UVB-induced pigmentation of guinea pig skin.  
**11:15 - 11:30** Achim H-P Krauss - Differential responses in normal human melanocytes to prostaglandin F2a and Endothelin-1.  
**11:30 - 11:45** Peter G. Parsons - Action of sunscreens on cells cultured from human skin.  
**11:45 - 12:00** P. A. Riley - Tyrosinase kinetics: a theoretical model of the mechanism with special reference to the lag period.
- 9:35 - noon** **CONCURRENT SESSION** - Lessons Learned from Vitiligo  
 Organizers Pran Das and Carolyn Le Poole  
 Mockingbird Room C
- 9:35 - 9:50** Overview of the field  
**9:50 - 10:05** Pranab K. Das - Polarised type-1 skin homing T cell subsets are associated with melanocyte destruction in vitiligo
- 10:05 - 10:30** BREAK in the break room - **POSTER VIEWING**
- 10:30 - 10:45** Gisela F. Erf - Effects of 5-azacytidine in Smyth line and parental brown line chickens.  
**10:45 - 11:00** Pranab K. Das - Autoimmunity to tumour immunity: Lesson from immunobiology of melanocyte in vitiligo.  
**11:00 - 11:15** Caroline LePool - Keratinocytes in lesional vitiligo skin express reduced levels of CDw60.

- 11:15 - 11:30** D. Parsad - Topical calcipotriol and puvasol in the treatment of vitiligo.  
**11:30 - 11:45** Ramaiah Abburi - A highly successful new treatment of vitiligo - results of clinical trial.  
**11:45 - 12:00** James J. Nordlund - Vitiligo in Tanzania

**OPTIONAL BROWN-BAG TRIP TO SEE THE MELANOMA PIGS**

We do not know how many people will want to take advantage of this opportunity, so we ask that you make your own arrangements with the hotel to provide a takeout lunch. Transportation to and from the College of Veterinary Medicine Research Park will be provided at the back door of the Hilton near the Theater.

- 2:00 - 2:20** Symposium: Melanoma: New Genes, Gene Therapy and Animal Models  
*Co-Chairs:* Meenhard Herlyn and Dennis Roop.  
 Theater
- 2:20 - 3:05** Invited Speaker Lynda Chin - Modeling malignant melanoma: Pathogenesis and maintenance. Theater
- 3:05 - 3:20** John Pawelek - A spontaneous murine melanoma lung metastasis comprised of host x tumor hybrids.
- 3:20 - 3:35** Steven Kazianis - Molecular genetics of xiphophorus fish melanoma models.
- 3:35 - 3:50** Carola Berking - Melanocyte activation and proliferation in human skin by overexpression of basic fibroblast growth factor in the dermis.
- 3:50 - 4:05** Mohamed Gamei - Treatment of acquired melanocytic nevi by Q-switched ruby laser.
- 4:05 - 4:30** BREAK in break room - **POSTER VIEWING**
- 4:30 - 4:45** Zhiqiang Wang - Alterations in gene expression in a monodelphis metastatic melanoma cell line.
- 4:45 - 5:00** Meenhard Herlyn - Photocarcinogenesis in human adult skin grafts.
- 5:00 - 5:45** Max Amoss - Here today -- gone tomorrow: the story of spontaneous regression of the melanoma of Sinclair swine.
- 6:00 - 6:45** Happy Hour, cash bar at the Hilton. Break Room.
- 6:45** Buses leave from the Hilton to the College of Veterinary Medicine for the Barbecue. No alcohol on campus -- don't miss the bus at the back door of the Hilton near the Theater.

**TUESDAY JUNE 27**

- 7:00 am** Continental Breakfast - Break Room
- 7:30 - 8:30** **SUNRISE SESSION** - Everyone come to the theater for a presentation by Dr. Alan Moshell, Director  
 Skin Diseases Branch  
 National Institute of Arthritis and Musculoskeletal and Skin Diseases  
 National Institutes of Health

- 8:30 am** Symposium: Melanoma: New Genes, Gene Therapy and Animal Models II  
*Co-Chairs:* Dot Bennett and StanPavel.  
Theater.
- 8:30 - 9:15** Invited Speaker Menashe Bar-Eli - Gene regulation in melanoma progression. Theater.
- 9:15-9:30** Stan Pavel - A multiple melanoma case with a germline homozygous CDKN2A gene/P16 mutation and glucose-6-phosphate dehydrogenase deficiency.
- 9:30-9:45** Debduitta Bandopadhyay - Human melanocytes exhibit an extended lifespan induced by telomerase expression.
- 9:45-10:00** Dorothy C. Bennett - Genetic manipulation of human melanocyte senescence.
- 10:00-10:15** Caroline LePoole - Antigen loss variants in melanoma: potential induction by interferon- $\alpha$ .
- 10:15 - 10:45** BREAK in break room - **POSTER VIEWING**
- 10:45-11:30** Keynote Address Dr. Osvaldo L. Podhajcer, University of Buenos Aires, Argentina.  
SPARC as a Target for Gene Therapy of Malignant Melanoma.  
Theater.
- 11:30-11:45** David J. Easty - Loss of expression of two closely related protein tyrosine and melanoma invasion.
- 11:45-12:00** P. K. Das - Tissue environment associated antigen and gene expression in melanocytic lesions?
- 12:00-12:15** Weidong Xu - Overexpression of the oncogene SKI in malignant melanomas: a mechanism to repress the response to TGF- $\beta$ .
- 12:15-1:30** LUNCH - Here it is - your chance to go out into the glorious sunshine and see the sights of metropolitan College Station. Or you may want to use this time for further discussion with Dr. Moshell or someone you otherwise never get to see in person.
- 1:30 - 1:50** Symposium: Vertebrate Genetics and Pigmentation  
*Co-Chairs:* Roz Miltenberger, Bill Pavan,  
Theater
- 1:50 - 2:25** Invited Speaker George Wolff - 1905-2000: regulation of pheomelanogenesis in yellow agouti mice.  
Theater
- 2:25 - 3:00** Special Lecture. To be announced.
- 3:00 - 3:30** BREAK in the break room. - **POSTER VIEWING**
- 3:30 - 4:15** Invited Speaker Roger Cone - Recent advances in melanocortin receptor structure and function.  
Theater
- 4:15 - 5:30** Invited Speaker Greg Barsh - Genetic and molecular basis of mammalian pigmentation patterns.

- Theater
- 5:30 - 5:45** Shosuke Ito - Interaction of major coat color gene products in mice as studied by chemical analysis of melanins.
- 5:45 - 6:00** Eugene Healy - Effects of human melanocortin 1 receptor variants on pigmentation in transgenic recessive yellow mice.
- 6:00 - 6:15** Rosalynn J. Miltenberger - Molecular analysis of hypomorphic, homozygous-viable alleles at the mouse agouti locus.

**7:30** BANQUET at Messina Hof Winery. Meet your buses at the back entrance to the Hilton near the Theater.

### WEDNESDAY, JUNE 28

- 8:00 am** Continental Breakfast, Break Room
- 8:30 - 9:15** Keynote Address Dr. Shin-Ichi Nishikawa, Department of Molecular Genetics, Faculty of Medicine, Kyoto University, Japan Patterns of Microenvironmental Factors Regulating Melanocyte Differentiation.  
Theater
- 9:15 - 9:35** Symposium: Melanosome Genesis, Function and Transfer to Keratinocytes  
*Co-Chairs:* Glynnis Scott and Seth Orlow.  
Theater
- 9:35 - 10:20** *Invited Speaker* Ray Boissy - Dissecting translocation signals via the Hermansky-Pudlak syndrome.  
Theater
- 10:20 - 10:35** Invited Speaker Miri Seiberg - The protease activated receptor-2 affects pigmentation by upregulating keratinocyte phagocytosis.  
Theater.
- 10:35 - 10:50** Ruth Halaban - Endoplasmic reticulum retention is a common defect associated with tyrosinase-negative albinism
- 10:50 - 11:05** Kazutomo Toyofuku - A new concept of the etiology of oculocutaneous albinism type I - sorting failure and degradation of mutant tyrosinases results in loss of enzyme activity.
- 11:05 - 11:20** Victoria M. Virador - Melanosomal uptake and sorting in co-cultures of melanocytes and keratinocytes.
- 11:20 - 11:35** Prashiela Manga - A role for the pink eyed-dilution gene product in transport of melanosomal proteins.
- 11:35 - 11:50** Ljiljana Minwalla - Inhibition of melanosome transfer to keratinocytes by lectins and neoglycoproteins in an in vitro model system.
- 11:50 - 12:05** M. C. Scott - Regulation of expression of the human melanocortin-1 receptor in epidermal melanocytes from different pigmentary phenotypes.
- 12:05 - 1:00** Meeting of the Membership.

Theater

**CHECKOUT TIME IS 12 NOON. YOU MAY LEAVE YOUR BAGS IN THE MOCKINGBIRD ROOM D.**

**POSTERS**

The posters may be set up in the break room on Sunday morning and should not be removed before the end of the meeting on Wednesday morning.

- T. Akiyama Endothelin receptor cDNA cloning from melanocytes of Medaka Fish, *Oryzias latipes*.  
Ernest V. Curto DermArrayTM: DNA microarray applications in pigment cell research.  
Jeannie Chan Characterization of the CDKN2A and ARF genes in UV-induced melanocytic hyperplasias and melanomas of a opossum (*Monodelphis domestica*).  
Pranab K. Das Melanocyte death by T-cell interactions in vitiligo.  
Gisela F. Erf Establishment and maintenance of feather melanocyte cultures from vitiliginous Smyth line and parental brown line chickens.  
Irma Gimenez-Conti Pigment pattern enhancement and MNU-induced tumor development in a novel *Xiphophorus* fish hybrid model.  
Nels Granholm Effects of MC1R modulators (desacetyl-alpha-MSH, alpha-MSH, and agouti protein) on melanogenesis in B16 melanoma cells.  
Michael J. Halverson Isolation, cloning and sequencing of porcine agouti-related protein gene (agrp).  
A. D. Heath Analysis of variation in melanin content and composition in Tpe V and VI photoprotected and photoexposed human skin.  
H. Z. Hill Increased eumelanin is photoprotective for survival of cloudman S91 mouse melanoma cells in UVB and protosensitizing in UVA.  
Jae-Sung Hwang A novel synthetic compound with anti-melanogenic property.  
Sungbin Im Histopathological characteristics of melasma.  
Yoko Kawa Stem cell factor dependent an immortal melanoblast cell line derived from mouse neural crest cells.  
Richard A. King OCA1:molecular studies of a complex phenotype.  
Tsuneto Kushimoto Melanosome mapping by purification of stage I/II melanosomes.  
Tie Chi Lei Studies on regulatory mechanisms of melanogenesis induced by 8-methoxypsoralen in co-cultures of melanocytes and keratinocytes.  
Brian Minyard Morphological evaluation of eyes of mice mutant at the *mitf* locus.  
Randall Morrison Correlations between iridophore ultrastructure and tissue color in zebrafish and two other danios.  
Nathan Parker Expression of Axolotl steel.  
Michael Pratt A microscopic survey of *Betta splendens* pigmentation.  
Xiao Quan The *albino* locus of the laboratory mouse.  
Edward S. Robinson Exposure thresholds for UV-induction of melanoma in the opossum model (*Monodelphis*).  
Rangaprasad Sarangarajan Recapitulation of Hermansky-Pudlak syndrome type I in melanoma cells transfected with antisense HPS1 cDNA.  
Denise J. Schwahn Transcriptional and post-transcriptional regulation of pigmentation-related genes during differentiation of human melanocytes  
Glynis Scott RAB3A and snare proteins: potential role in melanosome dynamics.  
Taketsugu Tadokoro Analysis of UV-induced DNA damage in skin within racial/ethnic groups.

Kazutomo Toyofuku Calnexin and TRP-1 interaction with Tyrosinase in various pigmented murine melanocytes: a model for mechanisms of hypopigmentation.  
Wilfred D. Vieira Effects of wine phenolic compounds on mouse and human melanomas.  
Xiaoli Wang Marek's disease virus infection of cultured chicken melanocytes.

## Bibliography :

The Bibliography published in this issue covers the period February through April, 2000. If you notice a paper that was not detected by this search that should be included, please send it to us and we will include it in the next issue. By its very nature, assignment of a reference to a particular category is arbitrary and we urge you to read through all categories to make sure you don't miss any pertinent to your field. We have attempted to highlight any publications which include a member of the PASPCR with a star (*sorry if we missed you but let us know and you'll get a free marked repeat in the next issue*).

### MELANINS, MELANOGENS & MELANOGENESIS

- Ahmed B, vandenOord JJ: Expression of the inducible isoform of nitric oxide synthase in pigment cell lesions of the skin. *BRIT J DERMATOL* 142:432-440 (2000).
- Aquaron R: Tradition of basic and applied pigment cell research in Marseilles. *CELL MOL BIOL* 45:877-882 (1999).
- Beermann F: The tyrosinase related protein-1 (Tyrp1) promoter in transgenic experiments: Targeted expression to the retinal pigment epithelium. *CELL MOL BIOL* 45:961-968 (1999).
- ❖ Benathan M, Virador V, Furumura M, Kobayashi N, Panizzon RG, Hearing VJ: Co-regulation of melanin precursors and tyrosinase in human pigment cells: Roles of cysteine and glutathione. *CELL MOL BIOL* 45:981-990 (1999).
- Birkle S, Gao LY, Zeng GC, Yu RK: Down-regulation of GD3 ganglioside and its O-acetylated derivative by stable transfection with antisense vector against GD3-synthase gene expression in hamster melanoma cells: Effects on cellular growth, melanogenesis, and dendricity. *J NEUROCHEM* 74:547-554 (2000).
- Brush L, Money NP: Invasive hyphal growth in *Wangiella dermatitidis* is induced by stab inoculation and shows dependence upon melanin biosynthesis. *FUNGAL GENET BIOL* 28:190-200 (1999).
- Bumsted KM, Barnstable CJ: Dorsal retinal pigment epithelium differentiates as neural retina in the Microphthalmia (mi/mi) mouse. *INVEST OPHTHALMOL VISUAL SCI* 41:903-908 (2000).
- Caird J, McDermott M, Farrell M March 2000: 5 month old boy with occipital bone mass - Diagnosis - Melanotic neuroectodermal tumour of infancy. *BRAIN PATHOL* 10:317+ (2000).
- Duchon J: Tradition of pigment cell research at Charles University in Prague. *CELL MOL BIOL* 45:883-894 (1999).
- Fetsch JF, Michal M, Miettinen M: Pigmented (melanotic) neurofibroma - A clinicopathologic and immunohistochemical analysis of 19 lesions from 17 patients. *AMER J SURG PATHOL* 24 :331-343 (2000).
- Mardin CY, Kuchle M, Nguyen NX, Martus P, Naumann GOH: Quantification of aqueous melanin granules, intraocular pressure and glaucomatous damage in primary pigment dispersion syndrome. *OPHTHALMOLOGY* 107:435-440 (2000).
- Mohagheghpour N, Waleh N, Garger SJ, Dousman L, Grill LK, Tusé D Synthetic melanin suppresses production of proinflammatory cytokines. *CELL IMMUNOL* 199:25-36 (2000).
- ❖ Park HY, Gilchrest BA: Signaling pathways mediating melanogenesis. *CELL MOL BIOL* 45:919-930 (1999).
- Qiu L, Zhang M, Sturm RA, Gardiner B, Tonks I, Kay G, Parsons PG: Inhibition of melanin synthesis by cystamine in human melanoma cells. *J INVEST DERMATOL* 114 :21-27 (2000).
- Qu XH, Kirschenbaum LJ, Borish ET: Hydroxyterephthalate as a fluorescent probe for hydroxyl radicals: Application to hair melanin. *PHOTOCHEM PHOTOBIOLOG* 71:307-313 (2000).
- Régnier M, Duval C, Galey JB, Philippe M, Lagrange A, Tuloup R, Schmidt R: Keratinocyte-melanocyte co-cultures and pigmented reconstructed human epidermis: Models to study modulation of melanogenesis. *CELL MOL BIOL* 45:969-980 (1999).
- Riley PA: The great DOPA mystery: The source and significance of DOPA in phase I melanogenesis. *CELL MOL BIOL* 45:951-960 (1999).
- ❖ Urbanska K, Romanowska-Dixon B, Elas M, Pajak S, Paziewski E, Bryk J, Kukielczak B, Slominski A, Zygulska-Mach H, Lukiewicz S: Experimental ruthenium plaque therapy of amelanotic and melanotic melanomas in the hamster eye. *MELANOMA RES* 10:26-35 (2000).
- Wegmann RJ: Melanins: an old problem revisited or the usefulness of infrared spectroscopy. *CELL MOL BIOL* 45:895-904 (1999).
- Zecca L, Costi P, Mecacci C, Ito S, Terreni M, Sonnino S: Interaction of human substantia nigra neuromelanin with lipids and peptides. *J NEUROCHEM* 74:1758-1765 (2000).

### MELANOCYTES & KERATINOCYTES

- Aizawa K, Nakamura T, Ohyama Y, Saito Y, Hoshino J, Kanda T, Sumino H, Nagai R: Renal artery stenosis associated with epidermal nevus syndrome. *NEPHRON* 84:67-70 (2000).
- Bergman R, Azzam H, Sprecher E, Manov L, Munichor M, Friedman-Birnbaum R, Ben Itzhak O: A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas. *J AMER ACAD DERMATOL* 42:496-500 (2000).



- Birindelli S, Tragni G, Bartoli C, Ranzani GN, Rilke F, Pierotti MA, Pilotti S: Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma. *INT J CANCER* 86:255-261 (2000).
- Boente MD, DeParra NP, DeLuna ML, Bonet HB, Muñoz AS, Parra V, Gramajo P, Moreno S, Asial RA: Phacomatosis pigmentokeratocica: another epidermal nevus syndrome and a distinctive type of twin spotting. *EUROPEAN J DERMATOLOGY* 10:190-194 (2000).
- ❖ Bowers RR, Nguyen B, Buckner S, Gonzalez Y, Ruiz F: Role of antioxidants in the survival of normal and vitiliginous avian melanocytes. *CELL MOL BIOL* 45:1065-1074 (1999).
- Broberg A, Augustsson A: Atopic dermatitis and melanocytic naevi. *BRIT J DERMATOL* 142:306-309 (2000).
- Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, Restifo NP, Zanovello P: Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. *CANCER RES* 60:253-258 (2000).
- Bykov VJ, Marcusson JA, Hemminki K: Effect of constitutional pigmentation on ultraviolet B-induced DNA damage in fair-skinned people. *J INVEST DERMATOL* 114:40-43 (2000).
- Cario-André M, Bessou S, Gontier E, Maresca V, Picardo M, Taïeb A: The reconstructed epidermis with melanocytes: A new tool to study pigmentation and photoprotection. *CELL MOL BIOL* 45:931-942 (1999).
- Daniel E, Ebenezer GJ, John ES, Job CK: Isolated focal melanocytes collection in the lacrimal sac. *BRIT J OPHTHALMOL* 84:337-337 (2000).
- Dhaene K, Vancoillie G, Lambert J, Naeyaert JM, VanMarck E: Absence of telomerase activity and telomerase catalytic subunit mRNA in melanocyte cultures. *BRIT J CANCER* 82:1051-1057 (2000).
- Diaz-Cano SJ: Melanocytes in squamous cell carcinoma of the skin. *BRIT J DERMATOL* 142:184-184 (2000).
- ❖ Halaban R: The regulation of normal melanocyte proliferation. *PIGM CELL RES* 13:4-14 (2000).
- Hirabayashi S, Shigematsu H, Iai M, Takashima S: A neurodegenerative disorder with early myoclonic encephalopathy, retinal pigmentary degeneration and nephronophthisis. *BRAIN DEVELOP* 22:24-30 (2000).
- ❖ Hu DN, Stjernschantz J, McCormick SA: Effect of prostaglandins A(2), E-1, F-2 $\alpha$  and latanoprost on cultured human iridal melanocytes. *EXPEYE RES* 70:113-120 (2000).
- Ingram DA, Yang FC, Travers JB, Wenning MJ, Hiatt K, New S, Hood A, Shannon K, Williams DA, Clapp DW: Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates *in vivo*. *J EXP MED* 191:181-187 (2000).
- Kaleem Z, Lind AC, Humphrey PA, Sueper RH, Swanson PE, Ritter JH, Wick MR: Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: An adjunct for recognition of the vertical growth phase in malignant melanomas? *MODERN PATHOL* 13:217-222 (2000).
- Kanter-Lewensohn L, Dricu A, Girnita L, Wejde J, Larsson O: Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27(Kip1) in melanocytic tumors: A potential regulatory role of IGF-1 pathway in distribution of p27(Kip1) between different cyclins. *GROWTH FACTORS* 17:193-202 (2000).
- Kelley SW, Cockerell CJ: Sentinel lymph node biopsy as an adjunct to management of histologically difficult to diagnose melanocytic lesions: A proposal. *J AMER ACAD DERMATOL* 42:527-530 (2000).
- Kittler H, Selteneim M, Dawid M, Pehamberger H, Wolff K, Binder M: Frequency and characteristics of enlarging common melanocytic nevi. *ARCH DERMATOL* 136:316-320 (2000).
- Kozlowski L, Wojtukiewicz MZ, Ostrowska H: Cathepsin A activity in primary and metastatic human melanocytic tumors. *ARCH DERMATOL RES* 292:68-71 (2000).
- Lambert J, Vancoillie G, Naeyaert JM: Molecular motors and their role in pigmentation. *CELL MOL BIOL* 45:905-918 (1999).
- Lin TYD, Dierickx CC, Campos VB, Farinelli WA, Rosenthal J, Anderson RR: Reduction of regrowing hair shaft size and pigmentation after ruby and diode laser treatment. *ARCH DERMATOL RES* 292:60-67 (2000).
- Loir B, Sanchez CP, Ghanem G, Lozano JA, Garcia-Borrón JC, Jimenez-Cervantes C: Expression of the MC1 receptor gene in normal and malignant human melanocytes. A semiquantitative RT-PCR study. *CELL MOL BIOL* 45:1083-1092 (1999).
- Meije CB, Mooi WJ, LePoole IC, vanMuijen GNP, Das PK: Micro-anatomy related antigen expression in melanocytic lesions. *J PATHOL* 190:572-578 (2000).
- Negro JJ, Tella JL, Blanco G, Forero MG, Garrido-Fernandez J: Diet explains interpopulation variation of plasma carotenoids and skin pigmentation in nestling white storks. *PHYSIOL BIOCHEM ZOOL* 73:97-101 (2000).
- Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, Hayward NK, Martin NG, Sturm RA: Melanocortin-1 receptor polymorphisms and risk of melanoma: Is the association explained solely by pigmentation phenotype? *AMER J HUM GENET* 66:176-186 (2000).
- Peters EMJ, Tobin DJ, Seidah NG, Schallreuter KU: Pro-opiomelanocortin-related peptides, prohormone convertases 1 and 2 and the regulatory peptide 7B2 are present in melanosomes of human melanocytes. *J INVEST DERMATOL* 114:430-437 (2000).
- Pilch H, Günzel S, Schäffer U, Tanner B, Heine M: Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging. *CANCER* 88:1370-1377 (2000).
- ❖ Rhodes AR: Common acquired nevocytic nevi and the fourth dimension. *ARCH DERMATOL* 136:400-405 (2000).
- Roberts JE, Wiechmann AF, Hu DN: Melatonin receptors in human uveal melanocytes and melanoma cells. *J PINEAL RES* 28:165-171 (2000).
- Schallreuter KU: A review of recent advances on the regulation of pigmentation in the human epidermis. *CELL MOL BIOL* 45:943-949 (1999).
- ❖ Seiberg M, Paine C, Sharlow E, Andrade-Gordon P, Costanzo M, Eisinger M, Shapiro SS: The protease-activated receptor 2 regulates pigmentation via keratinocyte-melanocyte interactions. *EXP CELL RES* 254:25-32 (2000).
- Shields CL, Cater J, Shields JA, Singh AD, Santos MCM, Carvalho C: Combination of clinical factors predictive of growth of small choroidal melanocytic tumors. *ARCH OPHTHALMOL* 118:360-364 (2000).
- Slingluff CL, Colella TA, Thompson L, Graham DD, Skipper JCA, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C, Harthun NL, Huczko EL, Hunt DF, Darrow TL, Engelhard VH: Melanomas with concordant loss of multiple melanocytic

- differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. *CANCER IMMUNOL IMMUNOTHER* 48:661-672 (2000).
- ❖ Sreekumar GP, Smyth JR, Ambady S, deLeon FAP: Analysis of the effect of endogenous viral genes in the Smyth line chicken model for autoimmune vitiligo. *AMER J PATHOL* 156:1099-1107 (2000).
  - Tsatmali M, Graham A, Szatkowski D, Ancans J, Manning P, McNeil CJ, Graham AM, Thody AJ:  $\alpha$ -Melanocyte-stimulating hormone modulates nitric oxide production in melanocytes. *J INVEST DERMATOL* 114:520-526 (2000).
  - Vancoillie G, Lambert J, Mulder A, Koerten HK, Mommaas AM, VanOostveldt P, Naeyaert JM: Kinesin and kinectin can associate with the melanosomal surface and form a link with microtubules in normal human melanocytes. *J INVEST DERMATOL* 114:421-429 (2000).
  - VonStrandmann EP, Senkel S, Ryffel GU: Ectopic pigmentation in *Xenopus* in response to DCoH/PCD, the cofactor of HNF1 transcription factor/pterin-4 $\alpha$ -carbinolamine dehydratase. *MECH DEVELOP* 91:53-60 (2000).
  - ❖ Wu M, Hemesath TJ, Takemoto CM, Horstmann MA, Wells AG, Price ER, Fisher DE, Fisher DE: c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. *GENE DEVELOP* 14:301-312 (2000).
  - ❖ Yang F, Sarangarajan R, LePoole IC, Medrano EE, Boissy RE: The cytotoxicity and apoptosis induced by 4-tertiary butylphenol in human melanocytes are independent of tyrosinase activity. *J INVEST DERMATOL* 114 :157-164 (2000).
  - Yoshida M, Takahashi Y, Inoue S: Histamine induces melanogenesis and morphologic changes by protein kinase A activation via H-2 receptors in human normal melanocytes. *J INVEST DERMATOL* 114:334-342 (2000).

## MELANOMA & METASTASIS

- Anonymous, Does sunlamp use increase the risk of cutaneous malignant melanoma? *ARCH DERM* 136:389-390 (2000).
- Ackerman AB: Mythology and numerology in the sphere of melanoma. *CANCER* 88:491-496 (2000).
- Alli PM, Crain BJ, Heitmiller R, Argani P: Malignant melanoma presenting as an intrathymic tumor - A primary thymic melanoma? *ARCH PATHOL LAB MED* 124:130-134 (2000).
- Allman R, Cowburn P, Mason M: *In vitro* and *in vivo* effects of a cyclic peptide with affinity for the  $\alpha v \beta 3$  integrin in human melanoma cells. *EUR J CANCER* 36:410-422 (2000).
- Amérigo J, Roig J, Pulido F, Belda R, Vázquez-Ramírez FJ, González-Cámpora R: Primary malignant melanoma of the adrenal gland. *SURGERY* 127:107-111 (2000).
- Anastassiou G, Schilling H, Stang A, Djakovic S, Heiligenhaus A, Bornfeld N: Expression of the cell adhesion molecules ICAM-1, VCAM-1 and NCAM in uveal melanoma: A clinicopathological study. *ONCOLOGY BASEL* 58:83-88 (2000).
- Assmann A, Farthmann B, Burkhardt O, Dippel E, Orfanos CE, Blume-Peytavi U: Cerebriform nodular amelanotic metastases of malignant melanoma: a challenge in differential diagnosis of a rare variant. *BRIT J DERMATOL* 142:533-536 (2000).
- Atkins MB: Interleukin-2 in metastatic melanoma: What is the current role? *CANCER J SCI AM* 6:S8-S10 (2000).
- Atkins MB, Kunkel L, Szoln M, Rosenberg SA: High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. *CANCER J SCI AM* 6:S11-S14 (2000).
- Autier P: Sunscreen and melanoma revisited. *ARCH DERMATOL* 136:423-423 (2000).
- Auzeloux P, Papon J, Azim EM, Borel M, Pasqualini R, Veyre A, Madelmont JC : A potential melanoma tracer: Synthesis, radiolabeling, and biodistribution in mice of a new nitridotechnetium bis(aminothioli) derivative pharmacomodulated by a N-(diethylaminoethyl)benzamide. *J MED CHEM* 43:190-198 (2000).
- ❖ Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Houghton A, Kirkwood JM, Mihm MF, Morton DL, Reintgen D, Ross MI, Sober A, Soong SJ, Thompson JA, Thompson JF, Gershenwald JE, McMasters KM: A new American Joint Committee on Cancer staging system for cutaneous melanoma. *CANCER* 88:1484-1491 (2000).
  - Barnard AL, Farzaneh F, Gäken J, Darling D: Local versus systemic interleukin-2: Tumor formation by wild-type and B7-1-positive murine melanoma cells. *CANCER GENE THERAPY* 7:207-214 (2000).
  - Bataille V, Snieder H, MacGregor AJ, Sasienski P, Spector TD: Genetics of risk factors for melanoma: An adult twin study of nevi and freckles. *J NAT CANCER INST* 92:457-463 (2000).
  - Benelli C, Roscetti E, DalPozzo V: Reproducibility of a dermoscopic method (7FFM) for the diagnosis of malignant melanoma. *EUROPEAN J DERMATOLOGY* 10:110-114 (2000).
  - Bernengo MG, Quaglino P, Cappello N, Lisa F, Osella-Abate S, Fierro MT: Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients. *MELANOMA RES* 10:55-65 (2000).
  - Bettinotti MP, Norris RD, Hackett JA, Thompson CO, Simonis TB, Stronck D, Marincola FM: Frequency of human leukocyte antigen-A 24 alleles in patients with melanoma determined by human leukocyte antigen-A sequence-based typing. *J IMMUNOTHER* 23:282-287 (2000).
  - Birck A, Ahrenkiel V, Zeuthen J, Hou-Jensen K, Guldberg P: Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. *J INVEST DERMATOL* 114:277-280 (2000).
  - Bishop JAN, Wachsmuth RC, Harland M, Bataille V, Pinney E, Mack P, Baglietto L, Cuzick J, Bishop DT: Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. *J INVEST DERMATOL* 114:28-33 (2000).
  - Bonvini P, Hwang SG, El Gamil M, Robbins P, Kim JS, Trepel J, Neckers L: Nuclear  $\beta$ -catenin displays GSK-3 $\beta$ - and APC-independent proteasome sensitivity in melanoma cells. *BBA MOL CELL RES* 1495:308-318 (2000).
  - Bosserhoff AK, Hauschild A, Hein R, Schadendorf D, Stockfleth E, Bogenrieder T, Landthaler M, Buettner R, Stolz W: Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas: Results of a German multicenter study. *J INVEST DERMATOL* 114 :395-396 (2000).
  - Brady MS, Lee F, Petrie H, Eckels DD, Lee JS: CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide *in vitro*. *CANCER IMMUNOL IMMUNOTHER* 48:621-626 (2000).

- Braybrooke JP, Houlbrook S, Crawley JE, Propper DJ, O'Byrne KJ, Stratford IJ, Harris AL, Shuker DEG, Talbot DC: Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. *CANCER CHEMOTHER PHARMACOL* 45:111-119 (2000).
- Brochez L, Naeyaert JM: Understanding the trends in melanoma incidence and mortality: where do we stand? *EUROPEAN J DERMATOLOGY* 10:71-76 (2000).
- Buhagiar JA, Podesta MTC, Wilson AP, Micallef MJ, Ali S: The induction of apoptosis in human melanoma, breast and ovarian cancer cell lines using an essential oil extract from the conifer *Tetraclinis articulata*. *ANTICANCER RES* 19:5435-5443 (1999).
- Bulliard JL: Site-specific risk of cutaneous malignant melanoma and pattern of sun exposure in New Zealand. *INT J CANCER* 85:627-632 (2000).
- Burkhardt CG, Burkhardt CN: Melanoma and insecticides: Is there a connection. *J AMER ACAD DERM* 42:302-303 (2000).
- Busetti A, Soncin M, Reddi E, Rodgers MAJ, Kenney ME, Jori G: Photothermal sensitization of amelanotic melanoma cells by Ni(II)-octabutoxy-naphthalocyanine. *J PHOTOCHEM PHOTOBIOLOG B BIOL* 53:103-109 (1999).
- Bussi M, Cardarelli L, Riontino E, Valente G: Primary malignant melanoma arising in the parotid gland: Case report and literature review. *TUMORI* 85:523-525 (1999).
- Capon F, Emonard H, Hornebeck W, Maquart FX, Bernard P: Expression and activation of pro-gelatinase A by human melanoma cell lines with different tumorigenic potential. *CLIN EXP METASTAS* 17:463-469 (1999).
- Carlson GW, Murray DR, Greenlee R, Alazraki N, Fry-Spray C, Poole R, Blais M, Hestley A, Vansant J: Management of malignant melanoma of the head and neck using dynamic lymphoscintigraphy and  $\gamma$  probe-guided sentinel lymph node biopsy. *ARCH OTOLAR HEAD NECK SURGERY* 126:433-437 (2000).
- Castillo M, Armao DM: Intraventricular melanoma - Reply. *AMER J NEURORADIOL* 21:608-608 (2000).
- Cattaruzza MS: Does sunlamp use increase the risk of cutaneous malignant melanoma? Editor's comment. *ARCH DERMATOL* 136:390-390 (2000).
- Chiquet C, Grange JD, Ayzac L, Chauvel P, Patricot LM, Devouassoux-Shisheboran M: Effects of proton beam irradiation on uveal melanomas: a comparative study of Ki-67 expression in irradiated versus non-irradiated melanomas. *BRIT J OPHTHALMOL* 84:98-102 (2000).
- Chu W, Pak BJ, Bani MR, Kapoor M, Lu SJ, Tamir A, Kerbel RS, Ben David Y: Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. *ONCOGENE* 19:395-402 (2000).
- Cirigliano G, DellaRossa A, Tavoni A, Viacava P, Bombardieri S: Polymositis occurring during  $\alpha$ -interferon treatment for malignant melanoma: a case report and review of the literature. *RHEUMATOL INT* 19:65-67 (1999).
- ❖ Cochran AJ, Elashoff D, Morton DL, Elashoff R: Individualized prognosis for melanoma patients. *HUM PATHOL* 31:327-331 (2000).
- Damato B: Disease and "dis-ease" in patients with uveal melanoma. *BRIT J OPHTHALMOL* 84:343-344 (2000).
- Demitsu T, Nagato H, Nishimaki K, Okada O, Kubota T, Yoneda K, Manabe M: Melanoma *in situ* of the penis. *J AMER ACAD DERMATOL* 42:386-388 (2000).
- Dithmar S, Rusciano D, Grossniklaus HE: A new technique for implantation of tissue culture melanoma cells in a murine model of metastatic ocular melanoma. *MELANOMA RES* 10:2-8 (2000).
- Dizdar N, Kullman A, Kagedal B: Comparison of N-acetylcysteine and L-2-oxothiazolidine-4-carboxylate as cysteine deliverers and glutathione precursors in human malignant melanoma transplants in mice. *CANCER CHEMOTHER PHARMACOL* 45:192-198 (2000).
- Dong XD, Tyler D, Johnson JL, DeMatos P, Seigler HF: Analysis of prognosis and disease progression after local recurrence of melanoma. *CANCER* 88:1063-1071 (2000).
- dosSantos NR, Torensma R, deVries TJ, Schreurs MWJ, deBuijn DRH, Kater-Baats E, Ruiters DJ, Adema GJ, vanMuijen GNP, vanKessel AG: Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. *CANCER RES* 60:1654-1662 (2000).
- Duteille F, Duport G, Goujon JM: Childhood malignant melanoma: an uncommon tumor. Three case reports. *PRESSE MEDICALE* 29:419-420 (2000).
- Eigtved A, Andersson AP, Dahlstrom K, Rabol A, Jensen M, Holm S, Sorensen SS, Drzewiecki KT, Hojgaard L, Friberg L: Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. *EUR J NUCL MED* 27:70-75 (2000).
- Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SRD, Ahern R, Smith IE, Gore ME: Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. *BRIT J CANCER* 82:812-817 (2000).
- Essner R, Bostick PJ, Glass EC, Foshag LJ, Haigh PI, Wang HJ, Morton DL: Standardized probe-directed sentinel node dissection in melanoma. *SURGERY* 127:26-31 (2000).
- Eton O, Buzaid AC, Bedikian AY, Smith TM, Papadopoulos NE, Ellerhorst JA, Hibberts JL, Legha SS, Benjamin RS: A phase II study of "decrecendo" interleukin-2 plus interferon- $\alpha$ -2a in patients with progressive metastatic melanoma after chemotherapy. *CANCER* 88:1703-1709 (2000).
- Eves P, Layton C, Hedley S, Dawson RA, Wagner M, Morandini R, Ghanem G, MacNeil S: Characterization of an *in vitro* model of human melanoma invasion based on reconstructed human skin. *BRIT J DERMATOL* 142:210-222 (2000).
- Fabrizi G, Massi G: Polypoid Spitz naevus: the benign counterpart of polypoid malignant melanoma. *BRIT J DERMATOL* 142:128-132 (2000).
- Feun LG, Savaraj M, Hurley J, Marini A, Lai SH: A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma. *CANCER* 88:584-588 (2000).
- Fidler IJ, Schackert G, Zhang R, Radinsky R, Fujimaki T: The biology of melanoma brain metastasis. *CANCER METAST REV* 18:387-400 (1999).

- Flaherty LE: Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy th cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma. *CANCER J SCI AM* 6:S15-S20 (2000).
- Fleury C, Bérard F, Balme B, Thomas L: The study of cutaneous melanomas in Camargue-type gray-skinned horses (1): Clinical-pathological characterization. *PIGM CELL RES* 13:39-46 (2000).
- Fleury C, Bérard F, Leblond A, Faure C, Ganem N, Thomas L: The study of cutaneous melanomas in Camargue-type gray-skinned horses (2): Epidemiological survey. *PIGM CELL RES* 13:47-51 (2000).
- Folini M, Colella G, Villa R, Lualdi S, Daidone MG, Zaffaroni N: Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells. *J INVEST DERM* 114:259-267 (2000).
- Foon KA, Lutzky J, Baral RN, Yannelli JR, Hutchins L, Teitelbaum A, Kashala OL, Das R, Garrison J, Reisfeld RA, Bhattacharya-Chatterjee M: Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. *J CLIN ONCOL* 18:376-384 (2000).
- Foss AJE, Lamping DL, Schroter S, Hungerford J: Development and validation of a patient based measure of outcome in ocular melanoma. *BRIT J OPHTHALMOL* 84:347-351 (2000).
- Gajewski TF: Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond. *CLIN DIAGN LAB IMMUNOL* 7:141-144 (2000).
- Gee MR, Pickard JS: Aeromedical decision-making for aviators with malignant melanoma: An update and review. *AVIAT SPACE ENVIRON MED* 71:245-250 (2000).
- Gennari R, Bartolomei M, Testori A, Zurrida S, Stoldt HS, Audisio RA, Geraghty JG, Paganelli G, Veronesi U: Sentinel node localization in primary melanoma: Preoperative dynamic lymphoscintigraphy, intraoperative  $\gamma$  probe, and vital dye guidance. *SURGERY* 127:19-25 (2000).
- Gillgren P, Månsson-Brahme E, Frisell J, Johansson H, Larsson O, Ringborg U: Epidemiological characteristics of cutaneous malignant melanoma of the head and neck - A population-based study. *ACTA ONCOL* 38:1069-1074 (1999).
- Gokaslan ZL, Aladag MA, Ellerhorst JA: Melanoma metastatic to the spine: a review of 133 cases. *MELANOMA RES* 10:78-80 (2000).
- Goldman BD: Melanoma and tumor thickness. *ARCH DERMATOL* 136:122-122 (2000).
- Gomori JM: Intraventricular melanoma. *AMER J NEURORADIOL* 21:607-607 (2000).
- Guibert P, Mollat F, Ligen M, Dreno B: Melanoma screening - Report of a survey in occupational medicine. *ARCH DERMATOL* 136:199-202 (2000).
- Haghnegahdar H, Du JG, Wang DZ, Strieter RM, Burdick MD, Nanney LB, Cardwell N, Luan J, Shattuck-Brandt R, Richmond A: The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. *J LEUKOCYTE BIOL* 67:53-62 (2000).
- ❖ Halaban R, Cheng E, Smicun Y, Germino J: Deregulated E2F transcriptional activity in autonomously growing melanoma cells. *J EXP MED* 191:1005-1015 (2000).
- Harland M, Holland EA, Ghiorzo P, Mantelli M, Bianchi-Scarr , Goldstein AM, Tucker MA, Ponder BAJ, Mann GJ, Bishop DT, Bishop JN: Mutation screening of the CDKN2A promoter in melanoma families. *GENE CHROMOSOME CANCER* 28:45-57 (2000).
- Hatoko M, Tanaka A, Kuwahara M, Tada H, Ohnishi T, Muramatsu T: Effect of epinephrine and combination treatment of epinephrine and heat on melanoma cell lines. Study of cytotoxicity and kinetics of 72-kD stress protein. *NEOPLASMA* 47:32-36 (2000).
- Heine B, Coupland SE, Kneiff S, Demel G, Bornfeld N, Hummel M, Stein H: Telomerase expression in uveal melanoma. *BRIT J OPHTHALMOL* 84:217-223 (2000).
- Heller R, Gilbert R, Jaroszeski MJ: Electrochemotherapy of murine melanoma using intratumor drug administration. *ELECTROCHEMOTHERAPY, ELECTROGENETHERAPY, AND TRANSDERMAL DRUG DELIVERY*. 253-257 (2000).
- Hipfel R, Schittek B, Bodingbauer Y, Garbe C: Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization. *BRIT J CANCER* 82:1149-1157 (2000).
- Hornbrey E, Banwell P, Gillespie P, Budny P: Melanoma follow-up: protocols and practice. *BRIT J DERMATOL* 142:585-586 (2000).
- Hurks HMH, Metzelaar-Blok JAW, Mulder A, Claas FHJ, Jager MJ: High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines. *INT J CANCER* 85:697-702 (2000).
- Ivanov VN, Kehrl JH, Ronai Z: Role of TRAF2/GCK in melanoma sensitivity to UV-induced apoptosis. *ONCOGENE* 19:933-942 (2000).
- Jäger E, Jäger D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjjatic S, Stockert E, Arand M, Old LJ, Knuth A: Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4\*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. *J EXP MED* 191:625-630 (2000).
- Johnson JP: Cell adhesion molecules in the development and progression of malignant melanoma. *CANCER METAST REV* 18:345-357 (1999).
- Kalechman Y, Longo DL, Catane R, Shani A, Albeck M, Sredni B: Synergistic anti-tumoral effect of paclitaxel (taxol)+AS101 in a murine model of B16 melanoma: Association with Ras-dependent signal-transduction pathways. *INT J CANCER* 86:281-288 (2000).
- Karniel M, Beitner R: Local anesthetics induce a decrease in the levels of glucose 1,6-bisphosphate, fructose 1,6-bisphosphate, and ATP, and in the viability of melanoma cells. *MOL GENET METAB* 69:40-45 (2000).
- Kataoka TR, Ito A, Asada H, Watabe K, Nishiyama K, Nakamoto K, Itami S, Yoshikawa K, Ito M, Nojima H, Kitamura Y: Annexin VII as a novel marker for invasive phenotype of malignant melanoma. *JPN J CANCER RES* 91:75-83 (2000).
- Kato M, Isobe K, Dai Y, Liu W, Takahashi M, Nakashima I: Further characterization of the Sho-saiko-to-mediated anti-tumor effect on melanoma developed in RET-transgenic mice. *J INVEST DERMATOL* 114:599-601 (2000).
- Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, Wunderlich JR, Yannelli JR, Rosenberg SA : Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. *J IMMUNOTHER* 23:17-27 (2000).

- Keilholz U, Eggermont AMM: The role of interleukin-2 in the management of stage IV melanoma: The EORTC Melanoma Cooperative Group program. *CANCER J SCI AM* 6:S99-S103 (2000).
- Keilholz U, Eggermont AMM: The emerging role of cytokines in the treatment of advanced melanoma. *ONCOLOGY BASEL* 58:89-95 (2000).
- Kikkawa H, Imafuku H, Tsukuda H, Oku N: Possible role of immune surveillance at the initial phase of metastasis produced by B16BL6 melanoma cells. *FEBS LETT* 467:211-216 (2000).
- Kuske MDA, Johnson JP: Assignment of the human melanoma cell adhesion molecule gene (MCAM) to chromosome 11 band q23.3 by radiation hybrid mapping. *CYTOGENET CELL GENET* 87:258-258 (1999).
- Lage H, Helmbach H, Dietel M, Schadendorf D: Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. *BRIT J CANCER* 82:488-491 (2000).
- Lal G, Liu L, Hogg D, Lassan NJ, Redston MS, Gallinger S: Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. *GENE CHROMOSOME CANCER* 27 :358-361 (2000).
- Lee ML, Tomsu K, VonEschen KB: Duration of survival for disseminated malignant melanoma: results of a meta-analysis. *MELANOMA RES* 10:81-92 (2000).
- Lee RJ, Gibbs JF, Proulx GM, Kollmorgen DR, Jia CY, Kraybill WG: Nodal basin recurrence following lymph node dissection for melanoma: Implications for adjuvant radiotherapy. *INT J RADIAT ONCOL BIOL PHYS* 46:467-474 (2000).
- Levit EK, Kagen MH, Scher RK, Grossman M, Altman E: The ABC rule for clinical detection of subungual melanoma. *J AMER ACAD DERMATOL* 42:269-274 (2000).
- Li G, Bush JA, Ho VC: p53-dependent apoptosis in melanoma cells after treatment with camptothecin. *J INVEST DERMATOL* 114:514-519 (2000).
- Linette GP, Shankara S, Longerich S, Yang SX, Doll R, Nicolette C, Preffer FI, Roberts BL, Haluska FG: *In vitro* priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A\*0201-restricted CD8(+) T cells in patients with melanoma. *J IMMUNOL* 164:3402-3412 (2000).
- ❖ Lyle S, Salhany KE, Elder DE: TIA-1 positive tumor-infiltrating lymphocytes in nevi and melanomas. *MODERN PATHOL* 13:52-55 (2000).
- Mackie RM: Melanoma and the dermatologist in the third millennium. *ARCH DERMATOL* 136:71-73 (2000).
- Madireddi MT, Dent P, Fisher PB: Regulation of mda-7 gene expression during human melanoma differentiation. *ONCOGENE* 19:1362-1368 (2000).
- Marghoob AA, Koenig K, Bittencourt FV, Kopf AW, Bart RS: Breslow thickness and Clark level in melanoma - Support for including level in pathology reports and in American Joint Committee on Cancer staging. *CANCER* 88:589-595 (2000).
- Matsuta M, Matsuta M, Akasaka T, Kagabu T: Changes in the cyclin D1 gene copy number in melanoma cell lines detected by double-target fluorescence *in situ* hybridization. *ACTA HISTOCHEM CYTOCHEM* 32:431-436 (1999).
- Mäurer J, Strauss A, Ebert W, Bauer H, Felix R: Contrast-enhanced high resolution magnetic resonance imaging of pigmented malignant melanoma using Mn-TPPS4 and Gd-DTPA: experimental results. *MELANOMA RES* 10:40-46 (2000).
- McDermott NC, Milburn C, Curran B, Kay EW, Walsh CB, Leader MB: Immunohistochemical expression of nm23 in primary invasive malignant melanoma is predictive of survival outcome. *J PATHOL* 190:157-162 (2000).
- Mecchia M, Matarrese P, Malorni W, D'Agostino G, Sestili P, Santini SM, Gauzzi MC, Venditti M, Parmiani G, Belardelli F, Ferrantini M: Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN- $\alpha$ . *GENE THERAPY* 7:167-179 (2000).
- ❖ Meier F, Nesbit M, Hsu MY, Martin B, VanBelle P, Elder DE, Schaumburg-Lever G, Garbe C, Walz TM, Donatien P, Crombleholme TM, Herlyn M: Human melanoma progression in skin reconstructs - Biological significance of bFGF. *AMER J PATHOL* 156:193-200 (2000).
- Middleton MR, Lorigan P, Owen J, Ashcroft L, Lee SM, Harper P, Thatcher N: A randomized phase III study comparing decarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. *BRIT J CANCER* 82:1158-1162 (2000).
- Moff SL, Corey GR, Gottfredsson M: Distant cutaneous granulomas after bacille Calmette-Guerin immunotherapy for malignant melanoma: Case for direct infection. *CLIN INFECT DIS* 29:1569-1570 (1999).
- Morandini R, Boeynaems JM, Duhant X, Jacquemotte F, Kinnaert E, Ghanem G: SODs are involved in the regulation of ICAM-1 expression in human melanoma and endothelial cells. *CELL MOL BIOL* 45:1053-1063 (1999).
- Morris JC, Ramsey WJ, Wildner Q, Muslow HA, Aguilar-Cordova E, Blaese RM: A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. *HUM GENE THER* 11:487-503 (2000).
- Murray JL, Hudson JM, Ross MI, Zhang HZ, Ioannides CG: Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: Relationship to TAP expression. *J IMMUNOTHER* 23:28-35 (2000).
- Nadjari B, Kersten A, Ross B, Motherby H, Krallmann R, Sundmacher R, Ophth FRC, Böcking A: Cytologic and DNA cytometric diagnosis and therapy monitoring of squamous cell carcinoma in &IT;itu&IT; and malignant melanoma of the cornea and conjunctiva (vol 21, pg 387, 1999). *ANAL QUANT CYTOL HISTOL* 22:91-91 (2000).
- Nagai H, Hara I, Horikawa T, Fujii M, Kurimoto M, Kamidono S, Ichihashi M: Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. *CANCER INVEST* 18:206-213 (2000).
- Nessling M, Kern MA, Schadendorf D, Lichter P: Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines. *CYTOGENET CELL GENET* 87:286-290 (1999).
- Négrier S, Fervers B, Bailly C, Beckendorf V, Cupissolv D, Doré JF, Dorval T, Garbay JR, Vilmer C: Standards, Options and Recommendations (SOR): clinical practice guidelines for diagnosis, treatment and follow-up of cutaneous melanoma. *BULL CANCER* 87:173-182 (2000).

- Ohnmacht GA, Marincola FM: Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma. *J CELL PHYSIOL* 182:332-338 (2000).
- Osanto S, Schiphorst PP, Weijl NI, Dijkstra N, VanWees A, Brouwenstein N, Vaessen N, VanKrieken JHJM, Hermans J, Cleton FJ, Schrier PI: Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. *HUM GENE THER* 11:739-750 (2000).
- Österlund C, Töhönen V, Forslund K, Nordqvist K: Mage-b4, a novel Melanoma antigen (MAGE) gene specifically expressed during germ cell differentiation. *CANCER RES* 60:1054-1061 (2000).
- ❖ Pacheco TR, Maxwell F, Vasiloudes PE, Robinson WA, Norris DA, Maxwell IH: Positive tetracycline control of expression of p15INK4B from an Epstein-Barr autonomous plasmid in a human melanoma cell line. *GENE* 242:249-256 (2000).
  - ❖ Pawelek JM, Chakraborty AK, Rachkovsky ML, Orlov SJ, Bolognia JL, Sodi SA: Altered N-glycosylation in macrophage X melanoma fusion hybrids. *CELL MOL BIOL* 45:1011-1027 (1999).
- Pennello G, Devesa S, Gail M: Association of surface ultraviolet B radiation levels with melanoma and nonmelanoma skin cancer in United States blacks. *CANCER EPIDEM BIOMARKER PREV* 9:291-297 (2000).
- Philip R, Alters SE, Brunette E, Ashton J, Gadea J, Yau J, Lebkowski J, Philip M: Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma. *J IMMUNOTHER* 23:168-176 (2000).
- Polk HC: Surgical progress and understanding in the treatment of the melanoma epidemic. *AMER J SURG* 178:443-448 (1999).
- Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO: Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. *INT J CANCER* 85:659-666 (2000).
- Ren SR, Smith MJ, Louro ID, McKie-Bell P, Bani MR, Wagner M, Zochodne B, Redden DT, Grizzle WE, Wang ND, Smith DI, Herbst RA, Bardenheuer W, Opalka B, Schütte J, Trent JM, Ben David Y, Ruppert JM: The p44(S10) locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma. *ONCOGENE* 19:1419-1427 (2000).
- Ribas A, Butterfield LH, Hu B, Dissette VB, Chen AY, Koh A, Amarnani SAN, Glaspy JA, McBride WH, Economou JS: Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. *J IMMUNOTHER* 23:59-66 (2000).
- Richard MA, Grob JJ: Melanoma and tumor thickness - In reply. *ARCH DERMATOL* 136:123-123 (2000).
- Richardson DR: The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell. *EUR J BIOCHEM* 267:1290-1298 (2000).
- ❖ Rieber M, Rieber MS: Tumor suppression without differentiation or apoptosis by antisense cyclin D1 gene transfer in K1735 melanoma involves induction of p53, p21WAF1 and superoxide dismutases. *CELL DEATH DIFFERENTIATION* 6:1209-1215 (1999).
- Russo E: Hot papers - Dendritic cell melanoma vaccine - Comment. *SCIENTIST* 14:18-18 (2000).
- Russo E: Hot papers - Synthetic peptide melanoma vaccine - Comment. *SCIENTIST* 14:18-19 (2000).
- Rübben A, Babilas P, Baron JM, Hofheinz A, Neis M, Sels F, Sporkert M: Analysis of tumor cell evolution in a melanoma: Evidence of mutational and selective pressure for loss of p16(ink4) and for microsatellite instability. *J INVEST DERMATOL* 114:14-20 (2000).
- Rünger TM, Emmert S, Schadendorf D, Diem C, Epe B, Hellfritsch D: Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. *J INVEST DERMATOL* 114:34-39 (2000).
- Santisteban A, Olaso E, Bidaurrazaga J, Rosenbaum J, Vidal-Vanaclocha F: Tumor-activated hepatic stellate cells upregulate *in vitro* proliferation and tubulization of sinusoidal endothelial cells and constitute a stromal support for neoangiogenesis in murine melanoma hepatic metastasis. *CELLS OF THE HEPATIC SINUSOID, VOL 7*. 41-42 (1999).
- ❖ Satyamoorthy K, Meier F, Hsu MY, Berking C, Herlyn M: Human xenografts, human skin and skin reconstructs for studies in melanoma development and progression. *CANCER METAST REV* 18:401-405 (1999).
- Savas B, Arslan G, Gelen T, Karpuzoglu G, Ozkaynak C: Multidrug resistant malignant melanoma with intracranial metastasis responding to immunotherapy. *ANTICANCER RES* 19:4413-4420 (1999).
- Scheibenbogen C, Schmittel A, Keilholz U, Allgäuer T, Hofmann U, Max R, Thiel E, Schadendorf D: Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. *J IMMUNOTHER* 23:275-281 (2000).
- Schmid-Wendtner MH, Wendtner CM, Sander C, Thetter O, Volkenandt M: Early detection of lymph node metastases by 7.5 MHz-ultrasound examination in a patient with primary malignant melanoma of the lung. *EUROPEAN J DERMATOLOGY* 10:143-145 (2000).
- Schmidt H, Geertsen PF, Fode K, Rytter C, Bastholt L, vonderMaase H: Subcutaneous interleukin-2 and interferon- $\alpha$  plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study. *MELANOMA RES* 10:66-77 (2000).
- Schwartz D, Beitner R: Detachment of the glycolytic enzymes, phosphofructokinase and aldolase, from cytoskeleton of melanoma cells, induced by local anesthetics. *MOL GENET METAB* 69:159-164 (2000).
- Sefton E, Glazebrook C, Garrud P, Zaki I: Educating patients about malignant melanoma: computer-assisted learning in a pigmented lesion clinic. *BRIT J DERMATOL* 142:66-71 (2000).
- Seftor REB, Seftor EA, Hendrix MJC: Molecular role(s) for integrins in human melanoma invasion. *CANCER METAST REV* 18:359-375 (1999).
- Seregard S, Oskarsson M, Spångberg B: Differential expression of nm23 H-1 protein in conjunctival melanoma and potential precursor lesions. *EXP EYE RES* 69:671-676 (1999).
- Sisley K, Parsons MA, Garnham J, Potter AM, Curtis D, Rees RC, Rennie IG: Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma. *BRIT J CANCER* 82:330-338 (2000).
- ❖ Smedley D, Sidhar S, Birdsall S, Bennett D, Herlyn M, Cooper C, Shipley J: Characterization of chromosome I abnormalities in malignant melanomas. *GENE CHROMOSOME CANCER* 28:121-125 (2000).

- Soufir N, Bressac-dePaillerets B, Desjardins L, Lévy C, Bombled J, Gorin I, Schlienger P, Stoppa-Lyonnet D: Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16(INK4A), P14(ARF) or cdk4 genes. *BRIT J CANCER* 82:818-822 (2000).
- Steitz J, Brück J, Steinbrink K, Enk A, Knop J, Tüting T: Genetic immunization of mice with human tyrosinase-related protein 2: Implications for the immunotherapy of melanoma. *INT J CANCER* 86:89-94 (2000).
- Strebhardt K, Kneisel L, Linhart C, Bernd A, Kaufmann R: Prognostic value of pololike kinase expression in melanomas. *JAMA J AM MED ASSN* 283:479-480 (2000).
- Tabandeh H, Chaudhry NA, Murray TG, Ehliès F, Hughes R, Scott IU, Markoe AM: Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. *AMER J OPHTHAL* 129:199-204 (2000).
- Takata M, Morita R, Takehara K: Clonal heterogeneity in sporadic melanomas as revealed by loss-of-heterozygosity analysis. *INT J CANCER* 85:492-497 (2000).
- Termeer CC, Schirrmacher V, Bröcker EB, Becker JC: Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. *CANCER GENE THERAPY* 7:316-323 (2000).
- Tjho-Heslinga RE, Davelaar J, Kemme HM, deVroome H, Oosterhuis JA, Bleeker JC, Leer JWH: Results of ruthenium irradiation of uveal melanomas: the Dutch experience. *RADIOOTHER ONCOL* 53:133-137 (1999).
- Tokumitsu H, Hiratsuka J, Sakurai Y, Kobayashi T, Ichikawa H, Fukumori Y: Gadolinium neutron-capture therapy using novel gadopentetic acid-chitosan complex nanoparticles: *in vivo* growth suppression of experimental melanoma solid tumor. *CANCER LETT* 150:177-182 (2000).
- Tordsson JM, Ohlsson LG, Abrahmsén LB, Karlström PJ, Lando PA, Brodin TN: Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma. *CANCER IMMUNOL IMMUNOTHER* 48:691-702 (2000).
- Tóth-Molnár E, Hammer H, Oláh J: Cutaneous dysplastic naevi in uveal melanoma patients: markers for prognosis? *MELANOMA RES* 10:36-39 (2000).
- Trefzer U, Weingart G, Chen YW, Herberth G, Adrian K, Winter H, Audring H, Guo YJ, Sterry W, Walden P: Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma. *INT J CANCER* 85:618-626 (2000).
- vanKempen LCLT, vandenOord JJ, vanMuijen GNP, Weidle UH, Bloemers HPJ, Swart GWM: Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. *AMER J PATHOL* 156:769-774 (2000).
- Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J, Carrascal T, Walsh P, Reznikov LL, Kim SH, Novick D, Rubinstein M, Dinarello CA: IL-18 regulates IL-1 $\beta$ -dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. *PROC NAT ACAD SCI USA* 97:734-739 (2000).
- Wagner JD, Park HM, Coleman JJ, Love C, Hayes JT: Cervical sentinel lymph node biopsy for melanomas of the head and neck and upper thorax. *ARCH OTOLAR HEAD NECK SURGERY* 126:313-321 (2000).
- Wagner JD, Gordon MS, Chuang TY, Coleman JJ: Current therapy of cutaneous melanoma. *PLAST RECONSTR SURG* 105:1774-1799 (2000).
- Wagner MS, Shoup M, Pickleman J, Yong S: Primary malignant melanoma of the common bile duct - A case report and review of the literature. *ARCH PATHOL LAB MED* 124:419-422 (2000).
- Walsh P, Gibbs P, Gonzalez R: Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease. *J AMER ACAD DERMATOL* 42:480-489 (2000).
- Wan YH, Emtage P, Zhu Q, Foley R, Pilon A, Roberts B, Gaudie J: Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. *CELL IMMUNOL* 198:131-138 (1999).
- Wang HX, Ng TB, Ooi VEC, Liu WK: Effects of lectins with different carbohydrate-binding specificities on hepatoma, choriocarcinoma, melanoma and osteosarcoma cell lines. *INT J BIOCHEM CELL BIOL* 32:365-372 (2000).
- Watari K, Tojo A, Nagamura-Inoue T, Nagamura F, Takeshita A, Fukushima T, Motoji T, Tani K, Asano S: Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. *FEBS LETT* 466:367-371 (2000).
- Wightman L, Patzelt E, Wagner E, Kircheis R: Development of transferrin-polycation/DNA based vectors for gene delivery to melanoma cells. *J DRUG TARGETING* 7:293-303 (1999).
- Wilkinson EJ: Protocol for the examination of specimens from patients with carcinomas and malignant melanomas of the vulva - A basis for checklists. *ARCH PATHOL LAB MED* 124:51-56 (2000).
- Wollina U, Karte K, Hipler UC, Knöll B, Kirsch K, Herold C: Serum protein S100 $\beta$  in patients with malignant melanoma detected by an immunoluminometric assay. *J CANCER RES CLIN ONCOL* 126:107-110 (2000).
- Wu ZY, Smithers BM, Anderson C, Roberts MS: Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment? *MELANOMA RES* 10:47-54 (2000).
- Yang CR, Wilson-VanPatten C, Planchon SM, Wuerzberger-Davis SM, Davis TW, Cuthill S, Miyamoto S, Boothman DA: Coordinate modulation of Sp1, NF-kappa B, and p53 in confluent human malignant melanoma cells after ionizing radiation. *FASEB J* 14:379-390 (2000).
- Yang P, Farkas DL, Kirkwood JM, Abernethy JL, Edington HD, Becker D: Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma. *MOL MED* 5:785-794 (1999).
- Zehntner S, Townsend J, Parkes J, Schmidt C, Down M, Bell J: Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy (vol 31, pg 116, 1999). *PATHOLOGY* 32:66-66 (2000).
- Zhou H, Gabazza EC, Sano T, Adachi Y, Suzuki K: Prothrombin promotes the invasiveness of melanoma cells by a different mechanism from thrombin. *FIBRINOLYSIS PROTEOLYSIS* 13:272-278 (1999).
- Zölzer F: Radiation and/or hyperthermia sensitivity of human melanoma cells after several days of incubation in media lacking serum or certain serum components. *INT J RADIAT ONCOL BIOL PHYS* 46:491-497 (2000).

## MSH, POMC, GROWTH FACTORS & RECEPTORS

- Adachi S, Morii E, Kim DK, Ogihara H, Jippo T, Ito A, Lee YM, Kitamura Y: Involvement of mi-transcription factor in expression of  $\alpha$ -melanocyte-stimulating hormone receptor in cultured mast cells of mice. *J IMMUNOL* 164:855-860 (2000).
- Alonso-Gómez AL, Valenciano AI, Alonso-Bedate M, Delgado MJ: Melatonin synthesis in the greenfrog retina in culture: II. Dopaminergic and adrenergic control. *LIFE SCI* 66:687-695 (2000).
- Argiolas A, Melis MR, Murgia S, Schlöth HB: ACTH- and  $\alpha$ -MSH-induced grooming, stretching, yawning and penile erection in male rats: Site of action in the brain and role of melanocortin receptors. *BRAIN RES BULL* 51:425-431 (2000).
- Bar-Eli M: Role of AP-2 in tumor growth and metastasis of human melanoma. *CANCER METAST REV* 18:377-385 (1999).
- Behrens UD, Douglas RH, Sugden D, Davies DJ, Wagner HJ: Effect of melatonin agonists and antagonists on horizontal cell spinule formation and dopamine release in a fish retina. *CELL TISSUE RES* 299:299-306 (2000).
- Blume-Jensen P, Jiang GQ, Hyman R, Lee KF, O'Gorman S, Hunter T: Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility. *NAT GENET* 24:157-162 (2000).
- Broberger C: Hypothalamic cocaine- and amphetamine-regulated transcript (CART) neurons: histochemical relationship to thyrotropin-releasing hormone, melanin-concentrating hormone, orexin/hypocretin and neuropeptide Y. *BRAIN RES* 848:101-113 (1999).
- Carr JA, Lovering AT:  $\mu$  and  $\delta$  opioid receptor regulation of pro-opiomelanocortin peptide secretion from the rat neurointermediate pituitary *in vitro*. *NEUROPEPTIDES* 34:69-75 (2000).
- Castel H, Louiset E, Anouar Y, LeFoll F, Cazin L, Vaudry H: Regulation of GABA(A) receptor by protein tyrosine kinases in frog pituitary melanotrophs. *J NEUROENDOCRINOL* 12:41-52 (2000).
- deWilt JHW, tenHagen TLM, deBoeck G, vanTiel ST, deBruijn EA, Eggermont AMM: Tumour necrosis factor  $\alpha$  increases melphalan concentration in tumour tissue after isolated limb perfusion. *BRIT J CANCER* 82:1000-1003 (2000).
- Farioli M, Venereo Y, Orta X, Castellanos JM, Segovia-Silvestre T: *In vitro* effects of melatonin on cell proliferation in a colon adenocarcinoma line. *J APPL TOXICOL* 20:21-24 (2000).
- Faust R, Garratt PJ, Jones R, Yeh LK, Tsotinis A, Panoussopoulou M, Calogeropoulou T, Teh MT, Sugden D: Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles. *J MED CHEM* 43:1050-1061 (2000).
- Fekete C, Légrádi G, Mihály E, Huang QH, Tatro JB, Rand WM, Emerson CH, Lechan RM:  $\alpha$ -melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. *J NEUROSCI* 20:1550-1558 (2000).
- Gardi J, Khalil WK, Vecsernyés M, Gáspár L, Szécsi M, Julesz J: Molecular forms of  $\alpha$ -melanocyte-stimulating hormone in pheochromocytoma tissue. *ENDOCRINE RES* 26:71-79 (2000).
- ❖ Halaban R: Melanoma cell autonomous growth: The Rb/E2F pathway. *CANCER METAST REV* 18:333-343 (1999).
  - Hanada R, Nakazato M, Matsukura S, Murakami N, Yoshimatsu H, Sakata T: Differential regulation of melanin-concentrating hormone and orexin genes in the agouti-related protein/melanocortin-4 receptor system. *BIOCHEM BIOPHYS RES COMMUN* 268:88-91 (2000).
  - ❖ Haskell-Luevano C, Lim S, Yuan W, Cone RD, Hruby VJ: Structure activity studies of the melanocortin antagonist SHU9119 modified at the 6, 7, 8, and 9 positions. *PEPTIDES* 21:49-57 (2000).
  - Hohmann JG, Teal TH, Clifton DK, Davis J, Hruby VJ, Han GX, Steiner RA: Differential role of melanocortins in mediating leptin's central effects on feeding and reproduction. *AMER J PHYSIOL REGUL INTEGR C* 278:R50-R59 (2000).
  - Kim MS, Rossi M, Abusnana S, Sunter D, Morgan DGA, Small CJ, Edwards CMB, Heath MM, Stanley SA, Seal LJ, Bhatti JR, Smith DM, Ghatei MA, Bloom SR: Hypothalamic localization of the feeding effect of agouti-related peptide and  $\alpha$ -melanocyte-stimulating hormone. *DIABÈTES* 49:177-182 (2000).
  - Kissel H, Timokhina I, Hardy MP, Rothschild G, Tajima Y, Soares V, Angeles M, Whitlow SR, Manova K, Besmer P: Point mutation in Kit receptor tyrosine kinase reveals essential roles for Kit signaling in spermatogenesis and oogenesis without affecting other Kit responses. *EMBO J* 19:1312-1326 (2000).
  - Krude H, Grüters A: Implications of proopiomelanocortin (POMC) mutations in humans: The POMC deficiency syndrome. *TRENDS ENDOCRINOL METAB* 11:15-22 (2000).
  - Lee J, Danielson H, Sollars C, Alrubaian J, Balm P, Dores RM: Cloning of a neoteleost *Oreochromis mossambicus* proopiomelanocortin (POMC) cDNA reveals a deletion of the  $\eta$ -melanotropin region and most of the joining peptide region: implications for POMC processing. *PEPTIDES* 20:1391-1399 (1999).
  - Li Z, VanAelst L, Cline HT: Rho GTPases regulate distinct aspects of dendritic arbor growth in *Xenopus* central neurons *in vivo*. *NAT NEUROSCI* 3:217-225 (2000).
  - Lloyd AW: Combinatorial chemistry - Melanocortin-1 receptor agonists. *DRUG DISCOV TODAY* 5:86-87 (2000).
  - Luger TA, Kalden DH, Scholzen TE, Brzoska T:  $\alpha$ -melanocyte-stimulating hormone as a mediator of tolerance induction. *PATHOBIOLOGY* 67:318-321 (1999).
  - Lyons HJ, Lyons LF, Taraskevich PS: Potassium-induced secretion of melanocyte-stimulating hormone from the melanotrophs of the neurointermediate lobe of the lizard *Anolis carolinensis*. *GEN COMP ENDO* 116:396-402 (1999).
  - ❖ Marsh DJ, Miura GI, Yagaloff KA, Schwartz MW, Barsh GS, Palmiter RD: Effects of neuropeptide Y deficiency on hypothalamic agouti-related protein expression and responsiveness to melanocortin analogues. *BRAIN RES* 848:66-77 (1999).
  - ❖ Matsunaga J, Sinha D, Solano F, Santis C, Wistow G, Hearing V: Macrophage migration inhibitory factor (MIF) - Its role in catecholamine metabolism. *CELL MOL BIOL* 45:1035-1040 (1999).
  - Mårtensson LGE, Andersson RGG: Is Ca<sup>2+</sup> the second messenger in the response to melatonin in cuckoo wrasse melanophores? *LIFE SCI* 66:1003-1010 (2000).
  - Mendoza L, Carrascal T, Fuentes AM, Anasagasti MJ, Martin J, DeLuca M, Vidal-Vanaclocha F: Production of sinusoidal endothelium-stimulating factors enables B16 melanoma cells to metastasize in liver by interleukin-1-dependent mechanism. *CELLS OF THE HEPATIC SINUSOID, VOL 7*. 278-282 (1999).



- Mercer JG, Moar KM, Ross AW, Hoggard N, Morgan PJ: Photoperiod regulates arcuate nucleus POMC, AGRP, and leptin receptor mRNA in Siberian hamster hypothalamus. *AMER J PHYSIOL REGUL INTEGR C* 278:R271-R281 (2000).
- Otsuka T, Jakubczak J, Vieira W, Bottaro DP, Breckenridge D, Larochelle WJ, Merlino G: Disassociation of met-mediated biological responses *in vivo*: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. *MOL CELL BIOL* 20:2055-2065 (2000).
- Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, Heim MH: Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon- $\alpha$ . *INT J CANCER* 85:720-725 (2000).
- Rago JV, Vath GM, Tripp TJ, Bohach GA, Ohlendorf DH, Schlievert PM: Staphylococcal exfoliative toxins cleave  $\alpha$ - and  $\beta$ -melanocyte-stimulating hormones. *INFECTION IMMUNITY* 68:2366-2368 (2000).
- Schepers GE, Bullejos M, Hosking BM, Koopman P: Cloning and characterisation of the Sry-related transcription factor gene Sox8. *NUCL ACID RES* 28:1473-1480 (2000).
- Tsatmali M, Yukitake J, Thody AJ: ACTH1-17 is a more potent agonist at the human MC1 receptor than  $\alpha$ -MSH. *CELL MOL BIOL* 45:1029-1034 (1999).
- Weber F, Sepp N, Fritsch P: Vascular endothelial growth factor and basic fibroblast growth factor in melanoma. *BRIT J DERMATOL* 142:392-393 (2000).
- Yeo GSH, Farooqi IS, Challis BG, Jackson RS, O'Rahilly S: The role of melanocortin signalling in the control of body weight: evidence from human and murine genetic models. *QJM MON J ASSOC PHYSICIAN* 93:7-14 (2000).
- Ziober BL, Beviglia L: Expression of the  $\alpha$ 7 $\beta$ 1 laminin receptor suppresses melanoma growth and metastatic potential (vol 10, pg 479, 1999). *CELL GROWTH DIFFER* 11:135-135 (2000).

## DEVELOPMENTAL BIOLOGY

- Ashman LK, Ferraro P, Cole SR, Cambareri AC: Effects of mutant c-Kit in early myeloid cells (vol 34, pg 451, 1997). *LEUK LYMPHOMA* 37:233-243 (2000).
- Cao Y, Wang CY: The COOH-terminal transactivation domain plays a key role in regulating the *in vitro* and *in vivo* function of Pax3 homeodomain. *J BIOL CHEM* 275:9854-9862 (2000).
- Colucci F, DiSanto JP: The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells. *BLOOD* 95:984-991 (2000).
- Dorsky RI, Raible DW, Moon RT: Direct regulation of nacre, a zebrafish MITF homolog required for pigment cell formation, by the Wnt pathway. *GENE DEVELOP* 14:158-162 (2000).
- Ehrenreich H, Nau R, Dembowski C, Hasselblatt M, Barth M, Hahn A, Schilling L, Sir? AL, Br k W: Endothelin B receptor deficiency is associated with an increased rate of neuronal apoptosis in the dentate gyrus. *NEUROSCIENCE* 95:993-1001 (2000).
- Imamura F, Arimoto I, Fujiyoshi Y, Doi T: W276 mutation in the endothelin receptor subtype B impairs G(q) but not G(i) or G(o) coupling. *BIOCHEMISTRY USA* 39:686-692 (2000).
- Kelsh RN, Eisen JS: The zebrafish colourless gene regulates development of non-ectomesenchymal neural crest derivatives. *DEVELOPMENT* 127:515-525 (2000).
- Molet S, Furukawa K, Maghazechi A, Hamid Q, Giaid A: Chemokine- and cytokine-induced expression of endothelin 1 and endothelin-converting enzyme 1 in endothelial cells. *J ALLERG CLIN IMMUNOL* 105:333-338 (2000).
- ❖ Rhim H, Dunn KJ, Aronzon A, Mac S, Cheng M, Lamoreux ML, Tilghman SM, Pavan WJ: Spatially restricted hypopigmentation associated with an Ednrb(s)-modifying locus on mouse chromosome 10. *GENOME RES* 10:17-29 (2000).
- Vachtenheim J, Novotna H: Expression of genes for microphthalmia isoforms, Pax3 and MSG1, in human melanomas. *CELL MOL BIOL* 45:1075-1082 (1999).
- Wang T, Langley KE, Gourley WK, Klimpel GR: Stem cell factor (SCF) can regulate the activation and expansion of murine intraepithelial lymphocytes. *CYTOKINE* 12:272-280 (2000).

## DIFFERENTIATION

- Alexeev V, Igoucheva O, Domashenko A, Cotsarelis G, Yoon K: Localized *in vivo* genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide. *NAT BIOTECHNOL* 18:43-47 (2000).
- Amicarelli F, Gasbarri A, Masciocco L, Pompili A, Pacitti C, Carlucci G, Palumbo G, Miranda M: The effect of intrastriatal injection of liposome-entrapped tyrosinase on the dopamine levels in the rat brain. *CELL MOL BIOL* 45:1093-1097 (1999).
- Baumeister FAM, Stachel D, Schuster F, Schmid I, Schaller M, Wolff H, Weiss M, Belohradsky BH: Accelerated phase in partial albinism with immunodeficiency (Griscelli syndrome): genetics and stem cell transplantation in a 2-month-old girl. *EUR J PEDIAT* 159:74-78 (2000).
- Borovansky J, Hach P: Disparate behaviour of two melanosomal enzymes ( $\alpha$ -mannosidase and  $\eta$ -glutamyltransferase). *CELL MOL BIOL* 45:1047-1052 (1999).
- Branza-Nichita N, Negroi G, Petrescu AJ, Garman EF, Platt FM, Wormald MR, Dwek RA, Petrescu SM: Mutations at critical N-glycosylation sites reduce tyrosinase activity by altering folding and quality control. *J BIOL CHEM* 275:8169-8175 (2000).
- Bullock TNJ, Colella TA, Engelhard VH: The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. *J IMMUNOL* 164:2354-2361 (2000).
- Ding B, Ryder OA, Wang XX, Bai SC, Zhou SQ, Zhang YP: Molecular basis of albinism in the rhesus monkey. *MUTAT RES FUNDAM MOL MECH MUT* 449:1-6 (2000).
- ❖ Dinulescu DM, Cone RD: Agouti and agouti-related protein: Analogies and contrasts. *J BIOL CHEM* 275:6695-6698 (2000).
- Espin JC, Varón R, Fenoll LG, Gilabert MA, García-Ruiz PA, Tudela J, García-Cánovas F: Kinetic characterization of the substrate specificity and mechanism of mushroom tyrosinase. *EUR J BIOCHEM* 267:1270-1279 (2000).

- Fenoll LG, Rodríguez-López JN, Varón R, García-Ruiz PA, García-Cánovas F, Tudela J: Kinetic study of the oxidation of 3-hydroxyanisole catalysed by tyrosinase. *BIOPHYS CHEM* 84:65-76 (2000).
- Fu LJ, Mambrini M, Perrot E, Chourrout D: Stable and full rescue of the pigmentation in a medaka albino mutant by transfer of a 17 kb genomic clone containing the medaka tyrosinase gene. *GENE* 241:205-211 (2000).
- ❖ Fuller BB, Drake MA, Spaulding DT, Chaudhry F: Downregulation of tyrosinase activity in human melanocyte cell cultures by yohimbine. *J INVEST DERMATOL* 114 :268-276 (2000).
  - ❖ Gili A, Thomas PD, Ota M, Jimbow K: Comparison of *in vitro* cytotoxicity of N-acetyl and N-propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity. *MELANOMA RES* 10:9-15 (2000).
- Goswami GK, Sadler MA, Siegel S Small-bowel stricture in a woman with oculocutaneous albinism (Hermansky-Pudlak syndrome). *AMER J ROENTGENOL* 174:1163-1164 (2000).
- Hara M, Yaar M, Byers HR, Goukassian D, Fine RE, Gonsalves J, Gilchrist BA : Kinesin participates in melanosomal movement along melanocyte dendrites. *J INVEST DERMATOL* 114:438-443 (2000).
- Ito M, Oda K: An organic solvent resistant tyrosinase from *Streptomyces* sp REN-21: Purification and characterization. *BIOSCI BIOTECHNOL BIOCHEM* 64:261-267 (2000).
- Jiménez M, García-Carmona F Hydroxylating activity of tyrosinase and its dependence on hydrogen peroxide. *ARCH BIOCHEM BIOPHYS* 373:255-260 (2000).
- Kerr R, Stevens G, Manga P, Salm S, John P, Haw T, Ramsay M: Identification of P gene mutations in individuals with oculocutaneous albinism in sub-Saharan Africa. *HUM MUTAT* 15:166-172 (2000).
- Luchin A, Purdom G, Murphy K, Clark MY, Angel N, Cassady AI, Hume DA, Ostrowski MC: The microphthalmia transcription factor regulates expression of the tartrate-resistant acid phosphatase gene during terminal differentiation of osteoclasts. *J BONE MINER RES* 15:451-460 (2000).
- Madani W, Kermasha S, Bisakowski B: Inhibition of tyrosinase activity by a polyphenol esterase using selected phenolic substrates. *PHYTOCHEMISTRY* 52:1001-1008 (1999).
- Martinez-Esparza M, Solano F, Garcia-Borron JC: Independent regulation of tyrosinase by the hypopigmenting cytokines TGF $\beta$ 1 and TNF $\alpha$  and the melanogenic hormone  $\alpha$ -MSH in B16 mouse melanocytes. *CELL MOL BIOL* 45:991-1000 (1999).
- Negroiu G, Branza-Nichita N, Petrescu AJ, Dwek RA, Petrescu SM: Protein specific N-glycosylation of tyrosinase and tyrosinase-related protein-1 in B16 mouse melanoma cells. *BIOCHEM J* 344:659-665 (1999).
- Negroiu G, Branza-Nichita N, Costin GE, Titu H, Petrescu AJ, Dwek RA, Petrescu SM: Investigation of the intracellular transport of tyrosinase and tyrosinase related protein (TRP)-1. The effect of endoplasmic reticulum (ER)-glucosidases inhibition. *CELL MOL BIOL* 45:1001-1010 (1999).
- Nylander K, Bourdon JC, Bray SE, Gibbs NK, Kay R, Hart I, Hall PA: Transcriptional activation of tyrosinase and TRP-I by p53 links UV irradiation to the protective tanning response. *J PATHOL* 190:39-46 (2000).
- Oh J, Liu ZX, Feng GH, Raposo G, Spritz RA : The Hermansky-Pudlak syndrome (HPS) protein is part of a high molecular weight complex involved in biogenesis of early melanosomes. *HUM MOL GENET* 9:375-385 (2000).
- Perez-Gilabert M, Carmona FG: Characterization of catecholase and cresolase activities of eggplant polyphenol oxidase. *J AGR FOOD CHEM* 48:695-700 (2000).
- Prasolova LA, Jing S: The mottling coat-color mutation in silver foxes: A morphological study of guard hairs. *RUSS J GENET* 35:1092-1096 (1999).
- Reck-Peterson SL, Provance DW, Mooseker MS, Mercer JA: Class V myosins. *BBA MOL CELL RES* 1496:36-51 (2000).
- Riley PA: Tyrosinase kinetics: A semi-quantitative model of the mechanism of oxidation of monohydric and dihydric phenolic substrates. *J THEOR BIOL* 203:1-12 (2000).
- Rogers SL, Gelfand VI: Membrane trafficking, organelle transport, and the cytoskeleton . *CURR OPIN CELL BIOL* 12:57-62 (2000).
- Shimizu K, Kondo R, Sakai K: Inhibition of tyrosinase by flavonoids, stilbenes and related 4-substituted resorcinols: Structure-activity investigations. *PLANTA MED* 66:11-15 (2000).
- Spritz RA: Hermansky-Pudlak syndrome and pale ear: Melanosome-making for the millennium. *PIGM CELL RES* 13:15-20 (2000).
- ❖ Sugumar M, Nellaiappan K: Characterization of a new phenoloxidase inhibitor from the cuticle of *Manduca sexta*. *BIOCHEM BIOPHYS RES COMMUN* 268:379-383 (2000).
  - ❖ Takeda K, Takemoto C, Kobayashi I, Watanabe A, Nobukuni Y, Fisher DE, Tachibana M: Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance. *HUM MOL GENET* 9:125-132 (2000).
- Thorneby-Andersson K, Sterner O, Hansson C: Tyrosinase-mediated formation of a reactive quinone from the depigmenting agents, 4-tert-butylphenol and 4-tert-butylcatechol. *PIGM CELL RES* 13:33-38 (2000).
- vanRensburg WJ, Ferreira D, Malan E, Steenkamp JA: Tyrosinase catalysed biphenyl construction from flavan-3-ol substrates. *PHYTOCHEMISTRY* 53:285-292 (2000).
- Verastegui C, Bertolotto C, Bille K, Abbe P, Ortonne JP, Ballotti R: TFE3, a transcription factor homologous to microphthalmia, is a potential transcriptional activator of tyrosinase and Tyrp1 genes. *MOL ENDOCRINOL* 14:449-456 (2000).
- Wang F, Chen LF, Arcucci O, Harvey EV, Bowers B, Xu YH, Hammer JA, Sellers JR: Effect of ADP and ionic strength on the kinetic and motile properties of recombinant mouse myosin V. *J BIOL CHEM* 275:4329-4335 (2000).
- Wang GL, Aazaz A, Peng ZR, Shen P: Cloning and overexpression of a tyrosinase gene mel from *Pseudomonas maltophilia*. *FEMS MICROBIOL LETT* 185:23-27 (2000).
- ❖ Xu WD, Gong LM, Haddad MM, Bischof O, Campisi J, Yeh ETH, Medrano EE: Regulation of microphthalmia-associated transcription factor MITF protein levels by association with the ubiquitin-conjugating enzyme hUBC9. *EXP CELL RES* 255:135-143 (2000).

## MISCELLANEOUS

- Cohen C, Turner ML, Stratakis CA: Pigmented lesions of the conjunctiva in Carney's complex. *J AMER ACAD DERMATOL* 42:145-145 (2000).
- Faigle W, Raposo G, Amigorena S: Antigen presentation and lysosomal membrane traffic in the Chediak-Higashi syndrome. *PROTOPLASMA* 210:117-122 (2000).
- Gasparro FP: Sunscreens, skin photobiology, and skin cancer: The need for UVA protection and evaluation of efficacy. *ENVIRON HEALTH PERSPECT* 108:71-78 (2000).
- Holme RH, Thomson SJ, Davidson DR: Ectopic expression of Msx2 in chick retinal pigmented epithelium cultures suggests a role in patterning the optic vesicle. *MECH DEVELOP* 91:175-187 (2000).
- ❖ Kameyama K, Takami H: Pigmented granules in functional black adenoma of the adrenal gland: A histochemical and ultrastructural study. *ENDOCR PATHOL* 10:353-357 (1999).
- Murakami F, Baba T, Mizoguchi M: Ultraviolet-induced generalized acquired dermal melanocytosis with numerous melanophages. *BRIT J DERMATOL* 142:184-186 (2000).
- Pastural E, Ersoy F, Yalman N, Wulffraat N, Grillo E, Ozkinay F, Tezcan I, Gedik? lu G, Philippe N, Fischer A, deStBasile G: Two genes are responsible for Griscelli syndrome at the same 15q21 locus. *GENOMICS* 63:299-306 (2000).
- Schiffner R, Schiffner-Rohe J, Vogt T, Landthaler M, Wlotzke U, Cagnetta AB, Stolz W: Improvement of early recognition of lentigo maligna using dermatoscopy. *J AMER ACAD DERMATOL* 42:25-32 (2000).
- Soyer HP, Kenet RO, Wolf IH, Kenet BJ, Cerroni L: Clinicopathological correlation of pigmented skin lesions using dermoscopy. *EUROPEAN J DERMATOLOGY* 10:22-28 (2000).
- Wallace VP, Crawford DC, Mortimer PS, Ott RJ, Bamber JC: Spectrophotometric assessment of pigmented skin lesions: methods and feature selection for evaluation of diagnostic performance. *PHYS MED BIOL* 45:735-751 (2000).